Author: "Heurgue A" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Heurgue A"' showing total 196 results

Start Over Author "Heurgue A"

196 results on '"Heurgue A"'

1. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Author: Azevedo, Sergio, Braghiroli, Maria Ignez, Girotto, Gustavo, Bragagnoli, Arinilda, Branco, Ricardo, Faccio, Adilson, Moretto, Andrea, Skare, Nils, Dutra, Jamille, Viola, Luciana, Vianna, Karina, Meton, Fernando, Sette, Claudia, Faulhaber, Amanda, Tam, Vincent C., Couture, Felix, Biagi, Jim, Castel, Helene, Mulder, Karen, Ko, Yoo-Joung, Zbuk, Kevin, Welch, Stephen, Beaudoin, Annie, Heurgué, Alexandra, Assenat, Eric, Archambeaud, Isabelle, Tougeron, David, Peron, Jean-Marie, Gilabert, Marine, Bronowicki, Jean-Pierre, Cattan, Stephane, Blanc, Jean-Frederic, Bouattour, Mohamed, Phelip, Jean-Marc, Boige, Valerie, Michel, Pierre, Frin, Anne-Claire, De Toni, Enrico N., Berres, Marie-Luise, Vogel, Arndt, Berg, Thomas, Ettrich, Thomas, Waldschmidt, Dirk, Wedemeyer, Hans Heinrich, Worns, Marcus-Alexander, Bitzer, Michael, Weiss, Karl-Heinz, Lau, George, Chan, Stephen L., Yau, Thomas, Tai, Yin Ping, Lee, Ann Shing, Thungappa, Satheesh Chiradoni, N, Lokesh K., Sureshchand Ostwal, Vikas, Ashok, Kattimani Kiran, Mittal, Sushant, Goyal, Hari, Srinivasan, Sankar, Biswas, Ghanashyam, Mohan, Mallavarapu, Limaye, Sewanti, Asarawala, Nirav, Rimassa, Lorenza, Falcone, Alfredo, Gianni, Luca, Gasbarrini, Antonio, Daniele, Bruno, Avallone, Antonio, Paolo Frassineti, Giovanni Luca, Roila, Fausto, Kudo, Masatoshi, Kawaoka, Tomokazu, Morimoto, Manabu, Takikawa, Yasuhiro, Kato, Naoya, Yamashita, Tatsuya, Osaki, Yukio, Motomura, Kenta, Tateishi, Ryosuke, Ohkawa, Kazuyoshi, Wada, Yoshiyuki, Onishi, Hideki, Sasahira, Naoki, Inaba, Yoshitaka, Kurosaki, Masayuki, Tsuji, Kunihiko, Takei, Yoshiyuki, Aramaki, Takeshi, Hagihara, Atsushi, Furuse, Junji, Kioka, Kiyohide, Koga, Hironori, Sasaki, Yutaka, Numata, Kazushi, Tada, Toshifumi, Kawaguchi, Yasunori, Nadano, Seijin, Vasilyev, Alexander, Breder, Valery, Lipatov, Oleg, Dvorkin, Mikhail, Zarubenkov, Oleg, Kutukova, Svetlana, Ponomarev, Roman, Shostka, Kirill, Alyasova, Anna, Topuzov, Eldar, Severtsev, Alexey, Petrov, Yuryi, Erygin, Dmitriy, Berdov, Boris, Kang, Yoon-Koo, Tak, Won-Young, Park, Joong-Won, Lim, Ho Yeong, Heo, Jeong, Kim, Jee Hyun, Kim, Tae-You, Choi, Hye Jin, Varela, María, Reig Monzon, María Elisa, Sangro, Bruno, Martin, Carlos Gómez, Ponce, Carmen Guillén, López, Carlos, Cheng, Ann-Lii, Chao, Yee, Feng, Yin-Hsun, Jeng, Long-Bin, Hung, Chao-Hung, Hou, Ming-Mo, Wang Tsang-En Wang, Jing-Houng, Yen, Chia-Jui, Sukeepaisarnjaroen, Wattana, Sunpaweravong, Patrapim, Charoentum, Chaiyut, Tanasanvimon, Suebpong, Sirachainan, Ekaphop, Ungtrakul, Teerapat, Prasongsook, Naiyarat, Maneenil, Kunlatida, Jitpewngarm, Wittawat, Ostapenko, Yurii, Skoryi, Denys, Bondarenko, Igor, Shparyk, Yaroslav, Trukhin, Dmytro, Hotko, Yevhen, Ursol, Grygorii, Kryzhanivska, Anna, Abou-Alfa, Ghassan K., Mody, Kabir, Dayyani, Farshid, Al-Rajabi, Raed, Yarchoan, Mark, Gandhi, Sunil, Crysler, Oxana, He, Aiwu Ruth, Reeves, James, Bahary, Nathan, Mahipal, Amit, Kelley, Robin Kate, Dasgupta, Anirudha, Rowe, Julie, Thota, Ramya, Beg, Muhammad, Morse, Michael, Choi, Sung-hee, Crocenzi, Todd, Somer, Bradley, Abrams, Thomas, Denlinger, Crystal, Zhang, Yue, Sharma, Nisha, Dao, Tu V., Thinh, Nguyen Tien, Tuyet Phuong, Le Thi, Sangro, B., Chan, S.L., Kelley, R.K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., Yarchoan, M., De Toni, E.N., Furuse, J., Kang, Y.K., Galle, P.R., Rimassa, L., Heurgué, A., Tam, V.C., Van Dao, T., Thungappa, S.C., Breder, V., Ostapenko, Y., Reig, M., Makowsky, M., Paskow, M.J., Gupta, C., Kurland, J.F., Negro, A., and Abou-Alfa, G.K.
Published: 2024
Full Text: View/download PDF

2. Recurrent splanchnic and extrasplanchnic thrombotic events in patients with non-cirrhotic portal vein thrombosis associated with local factors

Author: Ollivier-Hourmand, Isabelle, Lebedel, Louise, Alabau, Berta Bartroli, Goria, Odile, Bureau, Christophe, Dumortier, Jérome, Heurgué, Alexandra, Silvain, Christine, De-Ledinghen, Victor, Rautou, Pierre-Emmanuel, Payancé, Audrey, Ballester, Teresa García, Alvarado-Tapias, Edilmar, Hernández-Gea, Virginia, Valla, Dominique, Zekrini, Kamal, Nga Nguyen, Thi Thu, Dao, Thong, Garcia Pagan, Juan Carlos, Morello, Rémy, and Plessier, Aurélie
Published: 2024
Full Text: View/download PDF

3. Anterior Versus Classical Approach During Right Hepatectomy for Hepatocellular Carcinoma: Inverse Propensity Score Weighted Analysis

Author: Rhaiem, Rami, Sommacale, Daniele, Zimmermann, Perrine, Amroun, Koceila, Tashkandi, Ahmad, Laurent, Alexis, Amaddeo, Giuliana, Calderaro, Julien, Luciani, Alain, Heurgue, Alexandra, Thiefin, Gérard, Piardi, Tullio, Kianmanesh, Reza, and Brustia, Raffaele
Published: 2023
Full Text: View/download PDF

4. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

Author: Allende, Daniela S, Amaddeo, Giuliana, Argemi, Josepmaria, Baulande, Sylvain, Beaufrère, Aurélie, Bermúdez-Ramos, María, Boulagnon-Rombi, Camille, Boursier, Jérôme, Bruges, Léa, Calderaro, Julien, Campani, Claudia, Caruso, Stefano, Casadei-Gardini, Andrea, Castano Garcia, Andres, Chan, Stephen Lam, D'Alessio, Antonio, Di Tommaso, Luca, Diaz, Alba, Digklia, Antonia, Dufour, Jean-François, Garcia-Porrero, Guillermo, Ghaffari Laleh, Narmin, Gnemmi, Viviane, Gopal, Purva, Graham, Rondell P., Heurgué, Alexandra, Iavarone, Massimo, Iñarrairaegui, Mercedes, Kather, Jakob Nikolas, Klein, Christophe, Labgaa, Ismail, Lameiras, Sonia, Legoix, Patricia, Lequoy, Marie, Leung, Howard Ho-Wai, Loménie, Nicolas, Maggioni, Marco, Maille, Pascale, Marín-Zuluaga, Juan Ignacio, Mendoza-Pacas, Guillermo, Michalak, Sophie, Mínguez, Beatriz, El Nahhas, Omar S M, Nault, Jean-Charles, Navale, Pooja, Ningarhari, Massih, Paradis, Valérie, Park, Young Nyun, Pawlotsky, Jean-Michel, Pedica, Federica, Perbellini, Riccardo, Peter, Simon, Pinato, David James, Pinter, Matthias, Radu, Pompilia, Regnault, Hélène, Reig, Maria, Rela, Mohamed, Rhee, Hyungjin, Rimassa, Lorenza, Rimini, Margherita, Salcedo, María Teresa, Sangro, Bruno, Scheiner, Bernhard, Sempoux, Christine, Su, Tung-Hung, Torres, Callie, Tran, Nguyen H, Trépo, Eric, Varela, Maria, Verset, Gontran, Vij, Mukul, Vogel, Arndt, Wendum, Dominique, Zeng, Qinghe, and Ziol, Marianne
Published: 2023
Full Text: View/download PDF

5. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Author: Thompson, Alexander, Danta, Mark, Poursoltan, Pirooz, Kiberu, Andrew, Chittajallu, Renuka, Sood, Siddarth, Stauber, Rudolf, Pinter, Matthias, Peck-Radosavljevic, Markus, Decaestecker, Jochen, Cuyle, Pieter-Jan, Verset, Gontran, Van Vlierberghe, Hans, De Azevedo, Sergio, Andrade, Livia, Cunha Júnior, Ademar, Faria, Luiza, Yen, Cheng Tzu, Colli, Leandro, Asselah, Jamil, Kavan, Petr, Marquez, Vladimir, Brahmania, Mayur, Li, Qiang, Xing, Baocai, Guo, Yabing, Chen, Zhendong, Zhao, Haitao, Peng, Tao, Wang, Liming, Wang, Lu, Liu, Hongming, Wu, Feixiang, Qin, Lunxiu, Zheng, Qichang, Ying, Jieer, Li, Haitao, Wen, Tianfu, Qin, Shukui, Wen, Xiaoyu, Liu, Yunpeng, Chen, Minshan, Wang, Boqing, Bai, Yuxian, He, Yifu, Zhao, Hong, Zhou, Dong, Dai, Chaoliu, Teng, Gaojun, Cui, Shuzhong, Gao, Yi, Zhang, Xizhi, Lu, Zheng, Yin, Tao, Ding, Youming, Jia, Weidong, Xia, Yongxiang, Sun, Beicheng, Xia, Qiang, Yuan, Yufeng, Sun, Huichuan, Shi, Xuetao, Guzmán, Adrián, Corrales, Luis, Kral, Zdenek, Priester, Peter, Kubala, Eugen, Blanc, Jean Frederic, Bourliere, Marc, Peron, Jean Marie, Borg, Christophe, Bronowicki, Jean-Pierre, Ganne, Nathalie, Decaens, Thomas, Uguen, Thomas, Heurgue, Alexandra, Trojan, Joerg, Gonzalez-Carmona, Maria Angeles, Roderburg, Christoph, Ettrich, Thomas, Schotten, Clemens, Kandulski, Arne, Yau, Thomas, Chan, Lam, Scartozzi, Mario, Masi, Gianluca, Fanello, Silvia, Battezzati, Pier Maria, Leonardi, Francesco, Ghidini, Michele, Numata, Kazushi, Morimoto, Manabu, Hidaka, Hisashi, Tsuchiya, Kaoru, Yamashita, Tatsuya, Kato, Naoya, Kudo, Masatoshi, Hagihara, Atsushi, Koga, Hironori, Arakawa, Tomohiro, Nakamura, Ikuo, Kawamura, Yusuke, Kawaoka, Tomokazu, Shimada, Mitsuo, Hasegawa, Kiyoshi, Marusawa, Hiroyuki, Nakamura, Shinchiro, Hiraoka, Atsushi, Hayashi, Hiromitsu, Takeda, Shin, Lee, Han Chu, Paik, Seung Woon, Kim, Do Young, Lee, Jung Il, Jeong, Sook-Hyang, Kim, Won, Tak, Won Young, Heo, Jeong, Kim, Hyeyeong, Chon, Hong Jae, Cheong, Jaeyoun, Yoon, Seung Kew, Yoon, Jung-Hwan, Villalobos, Ricardo, Martinez Rodriguez, Jorge Luis, Oyervides Juarez, Victor, Hernández, Carlos Alberto, Klumpen, Heinz-Josef, de Vos-Geelen, Judith, Gane, Edward, Montenegro, Paola, Torres Mattos, Cesar, Janczewska, Ewa, Kawecki, Maciej, Nowakowska-Zajdel, Ewa, Fedenko, Alexander, Granov, Dmitrii, Alyasova, Anna, Sekacheva, Marina, Ledin, Evgeny, Samol, Jens, Toh, Han Chong, Calvo Campos, Mariona, Gomez Martin, Carlos, Lopez Lopez, Carlos, Muñoz Martin, Andres Jesus, Calleja Panero, Jose Luis, Montero Alvarez, Jose Luis, Reig Monzón, Maria, Delgado Mingorance, Ignacio, Minguez Rosique, Beatriz, Cheng, Ann Lii, Huang, Yi-Hsiang, Lin, Shi-Ming, Huang, Jee-Fu, Yu, Ming-Lung, Su, Wei-Wen, Korphaisarn, Krittiya, Maneenil, Kunlatida, Samdaengpan, Chayanee, Tharavichitkul, Ekkapong, Ozguroglu, Mustafa, Kose, Fatih, Harputluoglu, Hakan, Buchschacher, Gary, Thuluvath, Paul, Xiong, Henry, Patel, Mital, Gold, Philip, Li, Daneng, Brooks, Gabriel, Masood, Ashiq, Patel, Reema, George, Ben, Salgia, Reena, Manji, Gulam, Crow, Mary, Kaseb, Ahmed, Dugan, Matthew, Kadakia, Kunal, Kardosh, Adel, Gibbs, John, Shah, Ashesh, Burris III, Howard, Hsiehchen, David, Cheng, Ann-Lii, Kaseb, Ahmed O, Yopp, Adam C, Zhou, Jian, Nakamura, Shinichiro, Cha, Edward, Hack, Stephen P, Lian, Qinshu, Ma, Ning, Spahn, Jessica H, Wang, Yulei, Wu, Chun, and Chow, Pierce K H
Published: 2023
Full Text: View/download PDF

6. FRI-456 Characterization of the intratumoral immune microenvironment of hepatocellular carcinoma before selective intrahepatic radiation therapy (SIRT) and study of its prognostic value on response to treatment

Author: Franzè, Maria Stella, primary, Vigneron, Paul, additional, Caruso, Stefano, additional, Regnault, Hélène, additional, Sessa, Anna, additional, Maille, Pascale, additional, Bouda, Yasmine, additional, Iavarone, Massimo, additional, Canova, Lorenzo, additional, Maggioni, Marco, additional, Khac, Eric Nguyen, additional, Sarba, Ruxandra, additional, Yzet, Thierry, additional, Heurgue-berlot, Alexandra, additional, Kianmanesh, Reza, additional, Rhaiem, Rami, additional, Nault, Jean Charles, additional, Soussan, Michael, additional, Sutter, Olivier, additional, Allaire, Manon, additional, Lequoy, Marie, additional, Bouattour, Mohamed, additional, Beaufrère, Aurélie, additional, Burgio, Marco Dioguardi, additional, Raffaele, Brustia, additional, Sommacale, Daniele, additional, Luciani, Alain, additional, Tacher, Vania, additional, Pawlotsky, Jean-Michel, additional, Leroy, Vincent, additional, Calderaro, Julien, additional, and Amaddeo, Giuliana, additional
Published: 2024
Full Text: View/download PDF

7. THU-466 Treatment with Atezolizumab-Bevacizumab for hepatocellular carcinoma in the french population outside clinical trials: data from the prospective CHIEF cohort

Author: Allaire, Manon, primary, Hajer, Ben Khadhra, additional, Amaddeo, Giuliana, additional, Bouattour, Mohamed, additional, Brusset, Bleuenn, additional, Ziol, Marianne, additional, Merle, Philippe, additional, Blanc, Jean-Frédéric, additional, Uguen, Thomas, additional, Ganne-Carrié, Nathalie, additional, Cattan, Stéphane, additional, Riachi, Ghassan, additional, Loustaud-Ratti, Veronique, additional, Decaens, Thomas, additional, Silvain, Christine, additional, Peron, Jean Marie, additional, Baron, Aurore, additional, Pageaux, Georges-Philippe, additional, Oberti, Frédéric, additional, Anty, Rodolphe, additional, Manfredi, Sylvain, additional, Bourliere, Marc, additional, Ben Merabet, Yasmina, additional, Nousbaum, JeanB-aptiste, additional, Heurgue-Berlot, Alexandra, additional, Ollivier-Hourmand, Isabelle, additional, Ducournau, Gerard, additional, Ganry, Olivier, additional, Costentin, Charlotte, additional, and Khac, Eric Nguyen, additional
Published: 2024
Full Text: View/download PDF

8. OS-084-YI Hepatopulmonary syndrome in patients with porto-sinusoidal vascular disease: prevalence, characteristics, risk factors and outcome

Author: Spaes, Ylang, primary, Sidali, Sabrina, additional, El Husseini, Kinan, additional, Goria, Odile, additional, Mallet, Vincent, additional, Poujol-Robert, Armelle, additional, Gervais, Anne, additional, Lannes, Adrien, additional, Thabut, Dominique, additional, Nousbaum, Jean-Baptiste, additional, Ollivier-Hourmand, Isabelle, additional, Costentin, Charlotte, additional, Heurgue-berlot, Alexandra, additional, Houssel-Debry, Pauline, additional, Hillaire, Sophie, additional, Ganne-Carrié, Nathalie, additional, Drilhon, Nicolas, additional, Valainathan, Shantha, additional, Plessier, Aurélie, additional, Durand, Francois, additional, Raevens, Sarah, additional, Cachier, Agnes, additional, Elkrief, Laure, additional, and Rautou, Pierre-Emmanuel, additional
Published: 2024
Full Text: View/download PDF

9. Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma

Author: Assenat, Eric, Delhom-Christol, Elisabeth, Guiu, Boris, Ilonca, Alina D., Lonjon, Julie, Pageaux, Georges-Philippe, Abdel-Rehim, Mohamed, Al-laham, Wassim, Bouattour, Mohamed, Castera, Laurent, Dieudonné, Arnaud, Lebtahi, Rachida, Ronot, Maxime, Sibert, Annie, Vilgrain, Valérie, Barraud, Hélène, Bazin, Christophe, Bronowicki, Jean-Pierre, Laurent, Valérie, Mathias, Elodie, Chagneau-Derrode, Carine, Perdrisot, Rémy, Silvain, Christine, Tasu, Jean-Pierre, RenéGerolami, Patrick Borentain, Mundler, Olivier, Seitz, Jean-Francois, Vidal, Vincent, Aubé, Christophe, Bouvier, Antoine, Couturier, Olivier, Oberti, Frédéric, Vervueren, Laurent, Brenot-Rossi, Isabelle, Raoul, Jean-Luc, Sar-ran, Anthony, Chalaye, Julia, Costentin, Charlotte, Itti, Emmanuel, Kobeiter, Hicham, Luciani, Alain, Adam, René, Lewin, Maïté, Samuel, Didier, Edeline, Julien, Garin, Etienne, Rolland, Yan, Archambeaud, Isabelle, Eugene, Thomas, Frampas, Eric, Cassinotto, Christophe, Guyot, Martine, Hiriart, Jean-Baptiste, Lapuyade, Bruno, Vergniol, Julien, Bachellier, Philippe, Detour, Julien, Duclos, Bernard, Greget, Michel, Habersetzer, Francois, Imperiale, Alessio, Merle, Philippe, Rode, Agnès, Morvan, Julie, Nguyen-Khac, Eric, Yzet, Thierry, Baudin, Guillaume, Chevallier, Patrick, Mahamat, Abakar, Piche, Thierry, Razzouk, Micheline, Hillon, Patrick, Loffroy, Romaric, Toubeau, Michel, Vincent, Julie, Barabino, Gabriele, Bouarioua, Nadia, Cuilleron, Muriel, Ecochard, Marie, Prevot-Bitot, Nathalie, Leroy, Vincent, Roux, Julie, Sengel, Christian, Bourcier, Valérie, Carrie, Nathalie Ganne, Seror, Olivier, Costo, Sylvie, Dao, Thông, Pelage, Jean-Pierre, Dumortier, Jérôme, Giammarile, Francesco, Valette, Pierre-Jean, Ghazzar, Nadia, Pellerin, Olivier, Taieb, Julien, Weinmann, Pierre, Berlot, Alexandra Heurgue, Marcus, Claude, Sommacale, Daniele, Castilla-Lièvre, Maria-Angéla, Maitre, Sophie, Marthey, Lysiane, Zarca, Kevin, Mimouni, Maroua, Pereira, Helena, Chatellier, Gilles, and Durand-Zaleski, Isabelle
Published: 2021
Full Text: View/download PDF

10. Sustained Remission After Treatment Withdrawal in Autoimmune Hepatitis: A Multicenter Retrospective Study

Author: Ben Merabet, Yasmina, Barbe, Coralie, Heurgue-Berlot, Alexandra, Thévenot, Thierry, Minello, Anne, Habersetzer, François, Samuel, Didier, Bernard-Chabert, Brigitte, Weil-Verhoeven, Delphine, Renard, Pascal, Clot, Hélène, Di Martino, Vincent, Louvet, Hervé, Bresson-Hadni, Solange, and Thiéfin, Gérard
Published: 2021
Full Text: View/download PDF

11. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Author: Qin, Shukui, primary, Chen, Minshan, additional, Cheng, Ann-Lii, additional, Kaseb, Ahmed O, additional, Kudo, Masatoshi, additional, Lee, Han Chu, additional, Yopp, Adam C, additional, Zhou, Jian, additional, Wang, Lu, additional, Wen, Xiaoyu, additional, Heo, Jeong, additional, Tak, Won Young, additional, Nakamura, Shinichiro, additional, Numata, Kazushi, additional, Uguen, Thomas, additional, Hsiehchen, David, additional, Cha, Edward, additional, Hack, Stephen P, additional, Lian, Qinshu, additional, Ma, Ning, additional, Spahn, Jessica H, additional, Wang, Yulei, additional, Wu, Chun, additional, Chow, Pierce K H, additional, Thompson, Alexander, additional, Danta, Mark, additional, Poursoltan, Pirooz, additional, Kiberu, Andrew, additional, Chittajallu, Renuka, additional, Sood, Siddarth, additional, Stauber, Rudolf, additional, Pinter, Matthias, additional, Peck-Radosavljevic, Markus, additional, Decaestecker, Jochen, additional, Cuyle, Pieter-Jan, additional, Verset, Gontran, additional, Van Vlierberghe, Hans, additional, De Azevedo, Sergio, additional, Andrade, Livia, additional, Cunha Júnior, Ademar, additional, Faria, Luiza, additional, Yen, Cheng Tzu, additional, Colli, Leandro, additional, Asselah, Jamil, additional, Kavan, Petr, additional, Marquez, Vladimir, additional, Brahmania, Mayur, additional, Li, Qiang, additional, Xing, Baocai, additional, Guo, Yabing, additional, Chen, Zhendong, additional, Zhao, Haitao, additional, Peng, Tao, additional, Wang, Liming, additional, Liu, Hongming, additional, Wu, Feixiang, additional, Qin, Lunxiu, additional, Zheng, Qichang, additional, Ying, Jieer, additional, Li, Haitao, additional, Wen, Tianfu, additional, Qin, Shukui, additional, Liu, Yunpeng, additional, Wang, Boqing, additional, Bai, Yuxian, additional, He, Yifu, additional, Zhao, Hong, additional, Zhou, Dong, additional, Dai, Chaoliu, additional, Teng, Gaojun, additional, Cui, Shuzhong, additional, Gao, Yi, additional, Zhang, Xizhi, additional, Lu, Zheng, additional, Yin, Tao, additional, Ding, Youming, additional, Jia, Weidong, additional, Xia, Yongxiang, additional, Sun, Beicheng, additional, Xia, Qiang, additional, Yuan, Yufeng, additional, Sun, Huichuan, additional, Shi, Xuetao, additional, Guzmán, Adrián, additional, Corrales, Luis, additional, Kral, Zdenek, additional, Priester, Peter, additional, Kubala, Eugen, additional, Blanc, Jean Frederic, additional, Bourliere, Marc, additional, Peron, Jean Marie, additional, Borg, Christophe, additional, Bronowicki, Jean-Pierre, additional, Ganne, Nathalie, additional, Decaens, Thomas, additional, Heurgue, Alexandra, additional, Trojan, Joerg, additional, Gonzalez-Carmona, Maria Angeles, additional, Roderburg, Christoph, additional, Ettrich, Thomas, additional, Schotten, Clemens, additional, Kandulski, Arne, additional, Yau, Thomas, additional, Chan, Lam, additional, Scartozzi, Mario, additional, Masi, Gianluca, additional, Fanello, Silvia, additional, Battezzati, Pier Maria, additional, Leonardi, Francesco, additional, Ghidini, Michele, additional, Morimoto, Manabu, additional, Hidaka, Hisashi, additional, Tsuchiya, Kaoru, additional, Yamashita, Tatsuya, additional, Kato, Naoya, additional, Hagihara, Atsushi, additional, Koga, Hironori, additional, Arakawa, Tomohiro, additional, Nakamura, Ikuo, additional, Kawamura, Yusuke, additional, Kawaoka, Tomokazu, additional, Shimada, Mitsuo, additional, Hasegawa, Kiyoshi, additional, Marusawa, Hiroyuki, additional, Nakamura, Shinchiro, additional, Hiraoka, Atsushi, additional, Hayashi, Hiromitsu, additional, Takeda, Shin, additional, Paik, Seung Woon, additional, Kim, Do Young, additional, Lee, Jung Il, additional, Jeong, Sook-Hyang, additional, Kim, Won, additional, Kim, Hyeyeong, additional, Chon, Hong Jae, additional, Cheong, Jaeyoun, additional, Yoon, Seung Kew, additional, Yoon, Jung-Hwan, additional, Villalobos, Ricardo, additional, Martinez Rodriguez, Jorge Luis, additional, Oyervides Juarez, Victor, additional, Hernández, Carlos Alberto, additional, Klumpen, Heinz-Josef, additional, de Vos-Geelen, Judith, additional, Gane, Edward, additional, Montenegro, Paola, additional, Torres Mattos, Cesar, additional, Janczewska, Ewa, additional, Kawecki, Maciej, additional, Nowakowska-Zajdel, Ewa, additional, Fedenko, Alexander, additional, Granov, Dmitrii, additional, Alyasova, Anna, additional, Sekacheva, Marina, additional, Ledin, Evgeny, additional, Samol, Jens, additional, Toh, Han Chong, additional, Calvo Campos, Mariona, additional, Gomez Martin, Carlos, additional, Lopez Lopez, Carlos, additional, Muñoz Martin, Andres Jesus, additional, Calleja Panero, Jose Luis, additional, Montero Alvarez, Jose Luis, additional, Reig Monzón, Maria, additional, Delgado Mingorance, Ignacio, additional, Minguez Rosique, Beatriz, additional, Cheng, Ann Lii, additional, Huang, Yi-Hsiang, additional, Lin, Shi-Ming, additional, Huang, Jee-Fu, additional, Yu, Ming-Lung, additional, Su, Wei-Wen, additional, Korphaisarn, Krittiya, additional, Maneenil, Kunlatida, additional, Samdaengpan, Chayanee, additional, Tharavichitkul, Ekkapong, additional, Ozguroglu, Mustafa, additional, Kose, Fatih, additional, Harputluoglu, Hakan, additional, Buchschacher, Gary, additional, Thuluvath, Paul, additional, Xiong, Henry, additional, Patel, Mital, additional, Gold, Philip, additional, Li, Daneng, additional, Brooks, Gabriel, additional, Masood, Ashiq, additional, Patel, Reema, additional, George, Ben, additional, Salgia, Reena, additional, Manji, Gulam, additional, Crow, Mary, additional, Kaseb, Ahmed, additional, Dugan, Matthew, additional, Kadakia, Kunal, additional, Kardosh, Adel, additional, Gibbs, John, additional, Shah, Ashesh, additional, and Burris III, Howard, additional
Published: 2023
Full Text: View/download PDF

12. Pregnancy in idiopathic non-cirrhotic portal hypertension: A multicentric study on maternal and fetal management and outcome

Author: Andrade, Filipe, Shukla, Akash, Bureau, Christophe, Senzolo, Marco, D'Alteroche, Louis, Heurgué, Alexandra, Garcia-Pagan, Juan-Carlos, Turon, Fanny, Oberti, Frédéric, Tripathi, Dhiraj, Roux, Olivier, Ceccaldi, Pierre-François, de Raucourt, Emmanuelle, Payancé, Audrey, Valla, Dominique, Plessier, Aurélie, and Rautou, Pierre-Emmanuel
Published: 2018
Full Text: View/download PDF

13. Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis

Author: Efe, Cumali, Hagström, Hannes, Ytting, Henriette, Bhanji, Rahima A., Müller, Niklas F., Wang, Qixia, Purnak, Tugrul, Muratori, Luigi, Werner, Mårten, Marschall, Hanns-Ulrich, Muratori, Paolo, Gunşar, Fulya, Klintman, Daniel, Parés, Albert, Heurgué–Berlot, Alexandra, Schiano, Thomas D., Cengiz, Mustafa, May-Sien Tana, Michele, Ma, Xiong, Montano-Loza, Aldo J., Berg, Thomas, Verma, Sumita, Larsen, Fin Stolze, Ozaslan, Ersan, Heneghan, Michael A., Yoshida, Eric M., and Wahlin, Staffan
Published: 2017
Full Text: View/download PDF

14. Deep learning predicts sensitivity to atezolizumab-bevacizumab from digital slides of hepatocellular carcinoma

Author: Zeng, Qinghe, primary, Klein, Christophe, additional, Caruso, Stefano, additional, Maille, Pascale, additional, Allende, Daniela, additional, Minguez, Beatriz, additional, Iavarone, Massimo, additional, Ningarhari, Massih, additional, Gardini, Andrea Casadei, additional, Pedica, Federica, additional, Rimini, Margherita, additional, perbellini, Riccardo, additional, Boulagnon-Rombi, Camille, additional, Heurgue-berlot, Alexandra, additional, Maggioni, Marco, additional, Rela, Mohd., additional, Vij, Mukul, additional, Baulande, Sylvain, additional, Legoix, Patricia, additional, Lameiras, Sonia, additional, Labgaa, Ismail, additional, Sempoux, Christine, additional, Digkilia, Antonia, additional, Ghaffari-Laleh, Narmin, additional, Kather, Jakob Nikolas, additional, El Nahhas, Omar, additional, Navale, Pooja, additional, Torres, Callie, additional, Su, Tung-Hung, additional, Graham, Rondell, additional, Salcedo, María, additional, Bermúdez, María, additional, Tran, Nguyen H., additional, Pawlotsky, Jean-Michel, additional, Verset, Gontran, additional, Trépo, Eric, additional, Varela, Maria, additional, Castano-Garcia, Andrés, additional, Wendum, Dominique, additional, Amaddeo, Giuliana, additional, Regnault, Helene, additional, Lequoy, Marie, additional, Díaz, Alba, additional, Reig, María, additional, Radu, Pompilia, additional, Dufour, Jean-François, additional, Chan, Stephen, additional, Gopal, Purva, additional, Bruges, Léa, additional, Gnemmi, Viviane, additional, Nault, Jean Charles, additional, Rhee, Hyungjin, additional, Park, Young Nyun, additional, Iñarrairaegui, Mercedes, additional, Argemi, Josep Maria, additional, Sangro, Bruno, additional, D’Alessio, Antonio, additional, Scheiner, Bernhard, additional, Pinato, David J., additional, Pinter, Matthias, additional, Paradis, Valérie, additional, Beaufrère, Aurélie, additional, Peter, Simon, additional, Rimassa, Lorenza, additional, Di Tommaso, Luca, additional, Vogel, Arndt, additional, Michalak, Sophie, additional, Boursier, Jerome, additional, Loménie, Nicolas, additional, Ziol, Marianne, additional, and Calderaro, Julien, additional
Published: 2023
Full Text: View/download PDF

15. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

Author: Efe, C, Tascilar, K, Gerussi, A, Bolis, F, Lammert, C, Ebik, B, Stattermayer, A, Cengiz, M, Gokce, D, Cristoferi, L, Peralta, M, Massoumi, H, Montes, P, Cerda, E, Rigamonti, C, Yapali, S, Adali, G, Caliskan, A, Balaban, Y, Eren, F, Eskazan, T, Barutcu, S, Lytvyak, E, Zazueta, G, Kayhan, M, Heurgue-Berlot, A, De Martin, E, Yavuz, A, Biyik, M, Narro, G, Duman, S, Hernandez, N, Gatselis, N, Aguirre, J, Idilman, R, Silva, M, Mendizabal, M, Atay, K, Guzelbulut, F, Dhanasekaran, R, Montano-Loza, A, Dalekos, G, Ridruejo, E, Invernizzi, P, Wahlin, S, Efe C., Tascilar K., Gerussi A., Bolis F., Lammert C., Ebik B., Stattermayer A. F., Cengiz M., Gokce D. T., Cristoferi L., Peralta M., Massoumi H., Montes P., Cerda E., Rigamonti C., Yapali S., Adali G., Caliskan A. R., Balaban Y., Eren F., Eskazan T., Barutcu S., Lytvyak E., Zazueta G. M., Kayhan M. A., Heurgue-Berlot A., De Martin E., Yavuz A., Biyik M., Narro G. C., Duman S., Hernandez N., Gatselis N. K., Aguirre J., Idilman R., Silva M., Mendizabal M., Atay K., Guzelbulut F., Dhanasekaran R., Montano-Loza A. J., Dalekos G. N., Ridruejo E., Invernizzi P., Wahlin S., Efe, C, Tascilar, K, Gerussi, A, Bolis, F, Lammert, C, Ebik, B, Stattermayer, A, Cengiz, M, Gokce, D, Cristoferi, L, Peralta, M, Massoumi, H, Montes, P, Cerda, E, Rigamonti, C, Yapali, S, Adali, G, Caliskan, A, Balaban, Y, Eren, F, Eskazan, T, Barutcu, S, Lytvyak, E, Zazueta, G, Kayhan, M, Heurgue-Berlot, A, De Martin, E, Yavuz, A, Biyik, M, Narro, G, Duman, S, Hernandez, N, Gatselis, N, Aguirre, J, Idilman, R, Silva, M, Mendizabal, M, Atay, K, Guzelbulut, F, Dhanasekaran, R, Montano-Loza, A, Dalekos, G, Ridruejo, E, Invernizzi, P, Wahlin, S, Efe C., Tascilar K., Gerussi A., Bolis F., Lammert C., Ebik B., Stattermayer A. F., Cengiz M., Gokce D. T., Cristoferi L., Peralta M., Massoumi H., Montes P., Cerda E., Rigamonti C., Yapali S., Adali G., Caliskan A. R., Balaban Y., Eren F., Eskazan T., Barutcu S., Lytvyak E., Zazueta G. M., Kayhan M. A., Heurgue-Berlot A., De Martin E., Yavuz A., Biyik M., Narro G. C., Duman S., Hernandez N., Gatselis N. K., Aguirre J., Idilman R., Silva M., Mendizabal M., Atay K., Guzelbulut F., Dhanasekaran R., Montano-Loza A. J., Dalekos G. N., Ridruejo E., Invernizzi P., and Wahlin S.
Abstract: Background: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. Patients and methods: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression. Results: We included 413 (258 unvaccinated and 155 vaccinated) patients (81%, female) with a median age of 52 (range: 17–85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4% vs. 14.2%), need for any supplemental oxygen (29.5% vs. 9%) and mortality (7% vs. 0.6%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95% confidence interval [CI], 0.10–0.31). Overall, vaccination against SARS-CoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95% CI 0.11–0.35). Conclusions: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH.
Published: 2022

16. Cabozantinib (CABO) tolerance and efficacy for patients with advanced hepatocellular carcinoma (HCC) after failure of sorafenib (SOR) in a French population: CLERANCE, a phase 4 trial.

Author: Merle, Philippe, primary, Bouattour, Mohamed, additional, Blanc, Jean-Frédéric, additional, Peron, Jean-Marie, additional, Debette-Gratien, Marilyne, additional, Nahon, Pierre, additional, Nguyen-Khac, Eric, additional, Phelip, Jean Marc, additional, Assenat, Eric, additional, Bourgeois, Vincent, additional, Richou, Carine, additional, Heurgue, Alexandra, additional, Bronowicki, Jean-Pierre, additional, Ollivier-Hourmand, Isabelle, additional, Uguen, Thomas, additional, Cattan, Stéphane, additional, Thevenon, Sylvie, additional, Boucheny, Camille, additional, and Pradat, Pierre, additional
Published: 2023
Full Text: View/download PDF

17. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis

Author: George N. Dalekos, Cristina Rigamonti, Godolfino Miranda Zazueta, Ali Rıza Calışkan, Annarosa Floreani, Berat Ebik, Kadri Atay, Aylin Demirezer Bolat, Nazım Ekin, Eric M. Yoshida, Graciela Castro Narro, Fatih Güzelbulut, Murat Biyik, Manuel Mendizabal, Renumathy Dhanasekaran, Stefano Fagiuoli, Thomas D. Schiano, Ellina Lytvyak, Shalom Frager, Nataly Chris Escajadillo Vargas, Yucel Ustundag, Ramazan Idilman, Andreea M. Catana, Alvaro Urzúa, Ahmet Yavuz, Staffan Wahlin, Mesut Aydin, Cumali Efe, Laura Cristoferi, Hatef Massoumi, Maria Vincent, Sandro Ruiz Garcia, Evrim Kahramanoğlu-Aksoy, Natalia Ratusnu, Craig Lammert, Sümeyra Yıldırım, Mário Reis Álvares-da-Silva, Murat Harputoğlu, Marina Silveira, Murat Kiyici, Fátima Higuera-de la Tijera, Nurhan Demir, Cynthia Levy, Einar Bjornsson, Javier Brahm, Rotonya M. Carr, Nidah S. Khakoo, Andres Jose Gomez Aldana, Murat Akyildiz, Leyla Nazal, Alessio Gerussi, Tuğçe Eşkazan, Zeynep Ellik, Pietro Invernizzi, Fulya Gunsar, Ezequiel Ridruejo, Eleonora De Martin, Tugrul Purnak, Fatih Eren, Hüseyin Kaçmaz, Margarita Anders, Nikolaos K. Gatselis, Romee Snijders, Sezgin Barutçu, Costica Aloman, Alexandra Heurgue-Berlot, Bianca Magro, Jonathan Aguirre, Kader Irak, Koray Tascilar, Aldo J. Montano-Loza, Marcelo Silva, David N. Assis, Joost P.H. Drenth, Eira Cerda Reyes, Ibrahim Hatemi, Mirta Peralta, Sanjaya K. Satapathy, James L. Boyer, Yasemin H. Balaban, Efe, C, Lammert, C, Tascilar, K, Dhanasekaran, R, Ebik, B, Higuera-de la Tijera, F, Caliskan, A, Peralta, M, Gerussi, A, Massoumi, H, Catana, A, Purnak, T, Rigamonti, C, Aldana, A, Khakoo, N, Nazal, L, Frager, S, Demir, N, Irak, K, Melekoglu-Ellik, Z, Kacmaz, H, Balaban, Y, Atay, K, Eren, F, Alvares-da-Silva, M, Cristoferi, L, Urzua, A, Eskazan, T, Magro, B, Snijders, R, Barutcu, S, Lytvyak, E, Zazueta, G, Demirezer-Bolat, A, Aydin, M, Heurgue-Berlot, A, De Martin, E, Ekin, N, Yildirim, S, Yavuz, A, Biyik, M, Narro, G, Kiyici, M, Akyildiz, M, Kahramanoglu-Aksoy, E, Vincent, M, Carr, R, Gunsar, F, Reyes, E, Harputluoglu, M, Aloman, C, Gatselis, N, Ustundag, Y, Brahm, J, Vargas, N, Guzelbulut, F, Garcia, S, Aguirre, J, Anders, M, Ratusnu, N, Hatemi, I, Mendizabal, M, Floreani, A, Fagiuoli, S, Silva, M, Idilman, R, Satapathy, S, Silveira, M, Drenth, J, Dalekos, G, Assis, D, Bjornsson, E, Boyer, J, Yoshida, E, Invernizzi, P, Levy, C, Montano-Loza, A, Schiano, T, Ridruejo, E, Wahlin, S, Akyıldız, Murat (ORCID 0000-0002-2080-7528 & YÖK ID 123080), Efe, Cumalı, Lammert, Craig, Taşçılar, Koray, Dhanasekaran, Renumathy, Ebik, Berat, Higuera-de la Tijera, Fatima, Çalışkan, Ali R., Peralta, Mirta, Gerussi, Alessio, Massoumi, Hatef, Catana, Andreea M., Purnak, Tuğrul, Rigamonti, Cristina, Aldana, Andres J. G., Khakoo, Nidah, Nazal, Leyla, Frager, Shalom, Demir, Nurhan, Irak, Kader, Melekoğlu-Ellik, Zeynep, Kaçmaz, Hüseyin, Balaban, Yasemin, Atay, Kadri, Eren, Fatih, Alvares-da-Silva, Mario R., Cristoferi, Laura, Urzua, Alvaro, Eskazan, Tugce, Magro, Bianca, Snijders, Romee, Barutçu, Sezgin, Lytvyak, Ellina, Zazueta, Godolfino M., Demirezer-Bolat, Aylin, Aydın, Mesut, Heurgue-Berlot, Alexandra, De Martin, Eleonora, Ekin, Nazım, Yıldırım, Sumeyra, Yavuz, Ahmet, Bıyık, Murat, Narro, Graciela C., Kıyıcı, Murat, Kahramanoğlu-Aksoy, Evrim, Vincent, Maria, Carr, Rotonya M., Günsar, Fulya, Reyes, Eira C., Harputluoğlu, Murat, Aloman, Costica, Gatselis, Nikolaos K., Üstündağ, Yücel, Brahm, Javier, Vargas, Nataly C. E., Güzelbulut, Fatih, Garcia, Sandro R., Aguirre, Jonathan, Anders, Margarita, Ratusnu, Natalia, Hatemi, İbrahim, Mendizabal, Manuel, Floreani, Annarosa, Fagiuoli, Stefano, Silva, Marcelo, İdilman, Ramazan, Satapathy, Sanjaya K., Silveira, Marina, Drenth, Joost P. H., Dalekos, George N., Assis, David N., Bjornsson, Einar, Boyer, James L., Yoshida, Eric M., Invernizzi, Pietro, Levy, Cynthia, Montano-Loza, Aldo J., Schiano, Thomas D., Ridruejo, Ezequiel, Wahlin, Staffan, and School of Medicine
Subjects: Adult, Male, medicine.medical_specialty, budesonide, Cirrhosis, Adolescent, Gastroenterology and hepatology, medicine.medical_treatment, Azathioprine, Autoimmune hepatitis, mercaptopurine, Liver transplantation, Gastroenterology, Young Adult, Sars-Cov-2 Infection, Internal medicine, medicine, Humans, Autoimmunity, Budesonide, Mercaptopurine, SARS-CoV-2, Aged, Retrospective Studies, Mechanical ventilation, Aged, 80 and over, azathioprine, liver transplantation, Hepatology, business.industry, autoimmunity, COVID-19, Immunosuppression, Odds ratio, Middle Aged, medicine.disease, Tacrolimus, Liver-Transplant Recipients, Hospitalization, Hepatitis, Autoimmune, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], Pharmaceutical Preparations, Female, business, medicine.drug
Abstract: Background We investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH). Patients and methods Data of AIH patients with laboratory confirmed COVID-19 were retrospectively collected from 15 countries. The outcomes of AIH patients who were on immunosuppression at the time of COVID-19 were compared to patients who were not on AIH medication. The clinical courses of COVID-19 were classified as (i)-no hospitalization, (ii)-hospitalization without oxygen supplementation, (iii)-hospitalization with oxygen supplementation by nasal cannula or mask, (iv)-intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v)-ICU admission with invasive mechanical ventilation or (vi)-death and analysed using ordinal logistic regression. Results We included 254 AIH patients (79.5%, female) with a median age of 50 (range, 17-85) years. At the onset of COVID-19, 234 patients (92.1%) were on treatment with glucocorticoids (n = 156), thiopurines (n = 151), mycophenolate mofetil (n = 22) or tacrolimus (n = 16), alone or in combinations. Overall, 94 (37%) patients were hospitalized and 18 (7.1%) patients died. Use of systemic glucocorticoids (adjusted odds ratio [aOR] 4.73, 95% CI 1.12-25.89) and thiopurines (aOR 4.78, 95% CI 1.33-23.50) for AIH was associated with worse COVID-19 severity, after adjusting for age-sex, comorbidities and presence of cirrhosis. Baseline treatment with mycophenolate mofetil (aOR 3.56, 95% CI 0.76-20.56) and tacrolimus (aOR 4.09, 95% CI 0.69-27.00) were also associated with more severe COVID-19 courses in a smaller subset of treated patients. Conclusion Baseline treatment with systemic glucocorticoids or thiopurines prior to the onset of COVID-19 was significantly associated with COVID-19 severity in patients with AIH., Italian Ministry of University and Research (MIUR)-Department of Excellence project PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic), A. Gerussi, L. Cristoferi, and P. Invernizzi acknowledge that this research was partially supported by the Italian Ministry of University and Research (MIUR)-Department of Excellence project PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic).
Published: 2021

18. Structural and functional studies of Bud23-Trm112 reveal 18S rRNA N⁷-G1575 methylation occurs on late 40S precursor ribosomes

Author: Létoquart, Juliette, Huvelle, Emmeline, Wacheul,, Ludivine, Bourgeois, Gabrielle, Zorbas, Christiane, Graille, Marc, Heurgué-Hamard, Valérie, and Lafontaine, Denis L. J.
Published: 2014

19. Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial)

Author: Helena Pereira, Mohamed Bouattour, Marco D. Burgio, Eric Assenat, Jules Grégory, Jean-Pierre Bronowicki, Gilles Chatellier, Valérie Vilgrain, Elisabeth Delhom-Christol, Marjolène Fourcade, Boris Guiu, Alina Diana Ilonca, Julie Lonjon, Georges-Philippe Pageaux, Mohamed Abdel-Rehim, Wassim Allaham, Laurent Castera, Arnaud Dieudonné, Rachida Lebtahi, Maxime Ronot, Annie Sibert, Hélène Chor, Julie Devictor, Hélène Barraud, Christophe Bazin, Laetitia Imbert, Valérie Laurent, Elodie Mathias, Carine Chagneau-Derrode, Christelle Gallais, Rémy Perdrisot, Christine Silvain, Jean Pierre Tasu, Patrick Borentain, Bardia Farman, René Gerolami, Olivier Mundler, Jean-Francois Seitz, Vincent Vidal, Christophe Aubé, Francis Bouchet, Antoine Bouvier, Olivier Couturier, Frédéric Oberti, Laurent Vervueren, Isabelle Brenot-Rossi, Julien Darreon, Jean Luc Raoul, Anthony Sarran, Julia Chalaye, Charlotte Costentin, Emmanuel Itti, Hicham Kobeiter, Alain Luciani, Hélène Masset, René Adam, Maïté Lewin, Didier Samuel, Julien Edeline, Etienne Garin, Sophie Laffont, Yan Rolland, Isabelle Archambeaud, Thomas Carlier, Thomas Eugene, Eric Frampas, Christophe Cassinotto, Martine Guyot, Jean-Baptiste Hiriart, Bruno Lapuyade, Karine Tendero, Julien Vergniol, Philippe Bachellier, Julien Détour, Bernard Duclos, Michel Greget, Francois Habersetzer, Alessio Imperiale, Elise Enderlin, Philippe Merle, Agnès Rode, Julie Morvan, Eric Nguyen-Khac, Antoine Talbot, Thierry Yzet, Guillaume Baudin, Patrick Chevallier, Abakar Mahamat, Fabien Maurel, Thierry Piche, Micheline Razzouk, Patrick Hillon, Romaric Loffroy, Michel Toubeau, Julie Vincent, Jean-Marc Vrigneaud, Gabriele Barabino, Nadia Bouarioua, Muriel Cuilleron, Marie Ecochard, Nathalie Prevot-Bitot, Evelyne Rousset, Vincent Leroy, Ghislaine Reboulet, Julie Roux, Christian Sengel, Valérie Bourcier, Nathalie Ganne-Carrie, Olivier Seror, Sylvie Costo, Thông Dao, Cédric Desmonts, Jean-Pierre Pelage, Didier Defez, Jérôme Dumortier, Francesco Giammarile, Pierre-Jean Valette, Michela Bernardini, Nadia Ghazar, Olivier Pellerin, Julien Taieb, Pierre Weinmann, Alexandra Heurgue-Berlot, Claude Marcus, Daniele Sommacale, Maria-Angéla Castilla-Lièvre, Aurélie Forbes, Sophie Maitre, Lysiane Marthey, CIC - HEGP (CIC 1418), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPC), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Equipe IFTIM [ImViA - EA7535], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER-Imagerie et Vision Artificielle [Dijon] (ImViA), and Université de Bourgogne (UB)-Université de Bourgogne (UB)
Subjects: Male, Sorafenib, Cancer Research, medicine.medical_specialty, Carcinoma, Hepatocellular, Tare weight, [PHYS.PHYS.PHYS-BIO-PH]Physics [physics]/Physics [physics]/Biological Physics [physics.bio-ph], Locally advanced, Quality of life, Internal medicine, medicine, Humans, ComputingMilieux_MISCELLANEOUS, Aged, Social functioning, Health related quality of life, business.industry, Liver Neoplasms, Middle Aged, medicine.disease, Embolization, Therapeutic, digestive system diseases, Confidence interval, Oncology, Hepatocellular carcinoma, Quality of Life, Female, business, medicine.drug
Abstract: Background The aim of this ancillary study of the SARAH trial is to compare health-related quality of life (HRQoL) in patients with locally advanced or inoperable hepatocellular carcinoma (HCC) treated with transarterial radioembolisation (TARE) or sorafenib. Methods This study included randomised patients who received either TARE or at least one dose of sorafenib with no major deviation in the protocol and who had at least one QoL follow-up assessment in addition to the baseline evaluation. QoL was assessed from the date of randomisation using the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire, until disease progression or other reasons for stopping study participation. Data were analysed using linear mixed and time-dependent models. Results A total of 285 patients were included (122 and 163, in the TARE and sorafenib groups, respectively). Questionnaire completion rates were similar (77.5% versus 80.4%, in the TARE and sorafenib groups, respectively, p = 0.25). Longitudinal HRQoL analysis showed a significant treatment and time effects for fatigue and global health status, and significant treatment, time and treatment by time interaction effects for appetite loss, diarrhoea and social functioning. The median time to deterioration for the global health status was 3.9 months (95% confidence interval [CI] 3.7–4.3) versus 2.6 months (95% CI 2.0–3.0) in the TARE and sorafenib groups, respectively. Conclusions HRQoL was preserved longer with TARE than with sorafenib in locally advanced HCC. These data could be used to optimise management of patients with advanced or inoperable HCC.
Published: 2021

20. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

Author: Efe, Cumali, primary, Taşçılar, Koray, additional, Gerussi, Alessio, additional, Bolis, Francesca, additional, Lammert, Craig, additional, Ebik, Berat, additional, Stättermayer, Albert Friedrich, additional, Cengiz, Mustafa, additional, Gökçe, Dilara Turan, additional, Cristoferi, Laura, additional, Peralta, Mirta, additional, Massoumi, Hatef, additional, Montes, Pedro, additional, Cerda, Eira, additional, Rigamonti, Cristina, additional, Yapalı, Suna, additional, Adali, Gupse, additional, Çalışkan, Ali Rıza, additional, Balaban, Yasemin, additional, Eren, Fatih, additional, Eşkazan, Tuğçe, additional, Barutçu, Sezgin, additional, Lytvyak, Ellina, additional, Zazueta, Godolfino Miranda, additional, Kayhan, Meral Akdogan, additional, Heurgue-Berlot, Alexandra, additional, De Martin, Eleonora, additional, Yavuz, Ahmet, additional, Bıyık, Murat, additional, Narro, Graciela Castro, additional, Duman, Serkan, additional, Hernandez, Nelia, additional, Gatselis, Nikolaos K., additional, Aguirre, Jonathan, additional, Idilman, Ramazan, additional, Silva, Marcelo, additional, Mendizabal, Manuel, additional, Atay, Kadri, additional, Güzelbulut, Fatih, additional, Dhanasekaran, Renumathy, additional, Montano-Loza, Aldo J., additional, Dalekos, George N., additional, Ridruejo, Ezequiel, additional, Invernizzi, Pietro, additional, and Wahlin, Staffan, additional
Published: 2022
Full Text: View/download PDF

21. Évolution anatomo-radiologique d’une thrombose aiguë du réseau porte : suivi en TDM

Author: Attali, J., Heurgue, A., Loock, M., Thiefin, G., Marcus, C., and Long, A.
Published: 2014
Full Text: View/download PDF

22. Computed tomography follow-up of acute portal vein thrombosis

Author: Attali, J., Heurgue, A., Loock, M., Thiefin, G., Marcus, C., and Long, A.
Published: 2014
Full Text: View/download PDF

23. Factors Associated With Response to Therapy and Outcome of Patients With Primary Biliary Cirrhosis With Features of Autoimmune Hepatitis

Author: Ozaslan, Ersan, Efe, Cumali, Heurgué–Berlot, Alexandra, Kav, Taylan, Masi, Chiara, Purnak, Tugrul, Muratori, Luigi, Ustündag, Yücel, Bresson–Hadni, Solange, Thiéfin, Gérard, Schiano, Thomas D., Wahlin, Staffan, and Muratori, Paolo
Published: 2014
Full Text: View/download PDF

24. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis

Author: Soret, P, Lam, L, Carrat, F, Smets, L, Berg, T, Carbone, M, Invernizzi, P, Leroy, V, Trivedi, P, Cazzagon, N, Weiler-Normann, C, Alric, L, Rosa-Hezode, I, Heurgue, A, Cervoni, J, Dumortier, J, Potier, P, Roux, O, Silvain, C, Bureau, C, Anty, R, Larrey, D, Levy, C, Pares, A, Schramm, C, Nevens, F, Chazouilleres, O, Corpechot, C, Soret P. -A., Lam L., Carrat F., Smets L., Berg T., Carbone M., Invernizzi P., Leroy V., Trivedi P., Cazzagon N., Weiler-Normann C., Alric L., Rosa-Hezode I., Heurgue A., Cervoni J. -P., Dumortier J., Potier P., Roux O., Silvain C., Bureau C., Anty R., Larrey D., Levy C., Pares A., Schramm C., Nevens F., Chazouilleres O., Corpechot C., Soret, P, Lam, L, Carrat, F, Smets, L, Berg, T, Carbone, M, Invernizzi, P, Leroy, V, Trivedi, P, Cazzagon, N, Weiler-Normann, C, Alric, L, Rosa-Hezode, I, Heurgue, A, Cervoni, J, Dumortier, J, Potier, P, Roux, O, Silvain, C, Bureau, C, Anty, R, Larrey, D, Levy, C, Pares, A, Schramm, C, Nevens, F, Chazouilleres, O, Corpechot, C, Soret P. -A., Lam L., Carrat F., Smets L., Berg T., Carbone M., Invernizzi P., Leroy V., Trivedi P., Cazzagon N., Weiler-Normann C., Alric L., Rosa-Hezode I., Heurgue A., Cervoni J. -P., Dumortier J., Potier P., Roux O., Silvain C., Bureau C., Anty R., Larrey D., Levy C., Pares A., Schramm C., Nevens F., Chazouilleres O., and Corpechot C.
Abstract: Background: Obeticholic acid (OCA) and fibrates are second-line therapies for patients with primary biliary cholangitis (PBC) with an inadequate response to ursodeoxycholic acid (UDCA). Aim: To know whether OCA and fibrates, administered together in combination with UDCA, have additive beneficial effects in patients with difficult-to-treat PBC. Methods: PBC patients treated for ≥3 months with UDCA, OCA and fibrates (bezafibrate or fenofibrate) due to failure of either second-line therapy were included in a multicentre, uncontrolled retrospective cohort study. Changes in biochemical liver tests and pruritus were analysed using a generalised linear mixed-effect model. Results: Among 58 patients included, half received OCA as second-line and fibrates as third-line therapy (Group OCA-Fibrate), while the other half had the inverse therapeutic sequence (Group Fibrate-OCA). The mean duration of triple therapy was 11 months (range 3-26). Compared to dual therapy, triple therapy was associated with a significant gain in alkaline phosphatase (ALP) reduction: 22% per first year (95% CI 12%-31%), an effect that was stronger in OCA-Fibrate than in Fibrate-OCA group. Triple therapy was associated with a 3.4 (95% CI 1.4-8.2) odds ratio (OR) of reaching normal ALP and with a significant decrease in gamma-glutamyl transpeptidase (GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin. The ORs of achieving the Paris-2 and Toronto criteria of adequate biochemical response were 6.8 (95% CI 2.8-16.7) and 9.2 (95% CI 3.4-25.1) respectively. Finally, triple therapy significantly improved pruritus in OCA-Fibrate but not in Fibrate-OCA group. Conclusions: Triple therapy with UDCA, OCA and fibrates is able to normalise biochemical liver tests and improve pruritus in patients with difficult-to-treat PBC.
Published: 2021

25. Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score

Author: Olivier Chazouillères, Florent Artru, Eleonora De Martin, Philippe Mathurin, Camille Besch, Christophe Duvoux, François Durand, Odile Goria, Hélène Fontaine, Hélène Agostini, Isabelle Ollivier-Hourmand, Noemi Reboux, Olivier Roux, Filomena Conti, Nathalie Ganne-Carrié, Didier Samuel, Georges-Philippe Pageaux, Philippe Ichai, Marilyne Debette-Gratien, Christine Silvain, Alexandra Heurgue, Jean-Marie Peron, Sylvie Radenne, Jérôme Dumortier, Audrey Coilly, Pauline Houssel-Debry, Sandrine Barge, Marc Bourlière, Pascal Potier, Jean-Charles Duclos-Vallée, Vincent Di Martino, Mylène Sebagh, and Victor de Ledinghen
Subjects: 0301 basic medicine, medicine.medical_specialty, Multivariate analysis, Hepatology, medicine.drug_class, Bilirubin, business.industry, medicine.medical_treatment, Odds ratio, Autoimmune hepatitis, Liver transplantation, medicine.disease, 03 medical and health sciences, chemistry.chemical_compound, 030104 developmental biology, 0302 clinical medicine, chemistry, Internal medicine, medicine, Corticosteroid, 030211 gastroenterology & hepatology, Prospective cohort study, business, Survival rate
Abstract: Background & Aims In acute severe autoimmune hepatitis (AS-AIH), the optimal timing for liver transplantation (LT) remains controversial. The objectives of this study were to determine early predictive factors for a non-response to corticosteroids and to propose a score to identify patients in whom LT is urgently indicated. Methods This was a retrospective, multicenter study (2009-2016). A diagnosis of AS-AIH was based on: i) Definite or probable AIH based on the simplified IAIHG score; ii) international normalized ratio (INR) ≥1.5 and/or bilirubin >200 μmol/L; iii) No previous history of AIH; iv) Histologically proven AIH. A treatment response was defined as LT-free survival at 90 days. The evolution of variables from corticosteroid initiation (day-D0) to D3 was estimated from: Δ%3 = (D3–D0)/D0. Results A total of 128 patients were included, with a median age of 52 (39–62) years; 72% were female. Overall survival reached 88%. One hundred and fifteen (90%) patients received corticosteroids, with a LT-free survival rate of 66% at 90 days. Under multivariate analysis, D0-INR (odds ratio [OR] 6.85; 95% CI 2.23–21.06; p Conclusion In patients with AS-AIH, INR at the introduction of corticosteroids and the evolution of INR and bilirubin are predictive of LT or death. Within 3 days of initiating corticosteroids, the SURFASA score can identify non-responders who require a referral for LT. This score needs to be validated in a prospective cohort. Lay summary The management of patients with acute severe autoimmune hepatitis is highly challenging, particularly regarding their early referral for liver transplantation. We found that international normalized ratio at the initiation of corticosteroid therapy and the evolution of international normalized ratio and bilirubin values after 3 days of therapy were highly predictive of liver transplantation or death. We are thus proposing a score that combines these variables and identifies patients in whom liver transplantation is urgently required.
Published: 2021

26. Profiling serologic biomarkers in cirrhotic patients via high-throughput Fourier transform infrared spectroscopy: toward a new diagnostic tool of hepatocellular carcinoma

Author: Zhang, Xiaoqing, Thiéfin, Gérard, Gobinet, Cyril, Untereiner, Valérie, Taleb, Imane, Bernard-Chabert, Brigitte, Heurgué, Alexandra, Truntzer, Caroline, Ducoroy, Patrick, Hillon, Patrick, and Sockalingum, Ganesh D.
Published: 2013
Full Text: View/download PDF

27. High-risk Thrombophilia predict early thrombosis recurrence in acute non-cirrhotic portal vein thrombosis related to local factors: LOCAPORT

Author: Lebedel, Louise, primary, Plessier, Aurélie, additional, Goria, Odile, additional, Bureau, Christophe, additional, Heurgue-Berlot, Alexandra, additional, Rautou, Pierre-Emmanuel, additional, Payance, Audrey, additional, Zekrini, Kamal, additional, Nga Nguyen, Thi Thu, additional, Dao, Thong, additional, Morello, Rémi, additional, and Ollivier-Hourmand, Isabelle, additional
Published: 2022
Full Text: View/download PDF

28. New cases of Budd-Chiari syndrome and splanchnic vein thrombosis after COVID-19 vaccination-a vascular liver disease group (VALDIG) initiative

Author: Maan, Raoel, primary, Plessier, Aurélie, additional, China, Louise, additional, Patch, David, additional, Baiges, Anna, additional, Garcia Pagan, Juan Carlos, additional, Hernandez-Gea, Virginia, additional, Hilleret, Marie-Noëlle, additional, Tjwa, E.T.T.L., additional, Kounis, Ilias, additional, Bureau, Christophe, additional, Giguet, Baptiste, additional, Heurgue-Berlot, Alexandra, additional, Ollivier-Hourmand, Isabelle, additional, Causse, Xavier, additional, Castro Nery, Filipe Gaio, additional, Lauw, Mandy, additional, and Murad, Sarwa Darwish, additional
Published: 2022
Full Text: View/download PDF

29. Cabozantinib (CABO) tolerance and efficacy for patients with advanced hepatocellular carcinoma (HCC) after failure of sorafenib (SOR) in a French population: CLERANCE, a phase 4 trial

Author: Philippe Merle, Mohamed Bouattour, Jean-Frédéric Blanc, Jean-Marie Peron, Marilyne Debette-Gratien, Pierre Nahon, Eric Nguyen-Khac, Jean Marc Phelip, Eric Assenat, Vincent Bourgeois, Carine Richou, Alexandra Heurgue, Jean-Pierre Bronowicki, Isabelle Ollivier-Hourmand, Thomas Uguen, Stéphane Cattan, Sylvie Thevenon, Camille Boucheny, and Pierre Pradat
Subjects: Cancer Research, Oncology
Abstract: 573 Background: CABO is approved in second (2L) or third line (3L) systemic therapy for pts with advanced HCC after SOR failure, based on results of the CELESTIAL phase 3. CLERANCE was designed to evaluate safety and efficacy of CABO in pts with HCC in real-world practice in a French population. Methods: This prospective, French multicentre (n=17), interventional study aims to recruit 110 pts with unresectable HCC when a decision of CABO treatment was made in 2L or 3L after prior sorafenib (SOR) failure, according to the French health authority approved label. The primary endpoint is the incidence of treatment-related adverse events (TRAE) of grade > 2 (NCI-CTCAE v5) by a central review committee. Secondary endpoints include overall survival (OS), objective response rate (ORR) (RECIST v1.1 per investigator assessed), progression-free survival (PFS), time to progression (TTP) and profiles of CABO administration. Results: Of 110 pts enrolled, the final analysis focused on the 99 pts who starting CABO (11 pts withdrawn due to screen failure) and followed up to 12 mo (data cut-off: November 8, 2021). Pts were mainly males (89%), 69 years median age (range 24-85), Child-Pugh A (94.9%) / B7 (5.1%), and ALBI score-1 (33%), 2 (60%), 3 (5%), not evaluated (NE) (2%). About 59% pts received CABO in 2L after SOR, whereas 41% were in 3L after SOR and another line (TKI or IO). SOR was discontinued due to tumor progression (68%) or intolerance (32%) with a median duration of 4.2 mo (95% CI 3.5-4.8) and a median dose of 800 mg (95% CI 631-800). In the 99 pts starting CABO, 128 treatment-emergent adverse events (TEAE) of grade > 2 were reported, 40 of them classified as TRAE: hand foot skin reaction (14%), diarrhea (11%), asthenia and/or anorexia and/or weight loss (12%), arterial hypertension (4%). The ORR was 7% with 58% of disease control rate (DCR). Median PFS was 6.2 mo (95% CI, 5.3-8.7), TTP 8.2 mo (95% CI 6.1-12.8), without any difference when CABO used in 2L or 3L line (with prior IO [11%] or not). OS was 11.5 mo (95% CI 9.2-14.6) since start of CABO and 23 mo (95% CI 17.3-29.4) since the first systemic line. ALBI score at 1 was an independent marker of better OS in multivariate analysis (Exp[b] 3.26, 95% CI 1.86-5.69, p
Published: 2023

30. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

Author: Cumali Efe, Koray Taşçılar, Alessio Gerussi, Francesca Bolis, Craig Lammert, Berat Ebik, Albert Friedrich Stättermayer, Mustafa Cengiz, Dilara Turan Gökçe, Laura Cristoferi, Mirta Peralta, Hatef Massoumi, Pedro Montes, Eira Cerda, Cristina Rigamonti, Suna Yapalı, Gupse Adali, Ali Rıza Çalışkan, Yasemin Balaban, Fatih Eren, Tuğçe Eşkazan, Sezgin Barutçu, Ellina Lytvyak, Godolfino Miranda Zazueta, Meral Akdogan Kayhan, Alexandra Heurgue-Berlot, Eleonora De Martin, Ahmet Yavuz, Murat Bıyık, Graciela Castro Narro, Serkan Duman, Nelia Hernandez, Nikolaos K. Gatselis, Jonathan Aguirre, Ramazan Idilman, Marcelo Silva, Manuel Mendizabal, Kadri Atay, Fatih Güzelbulut, Renumathy Dhanasekaran, Aldo J. Montano-Loza, George N. Dalekos, Ezequiel Ridruejo, Pietro Invernizzi, Staffan Wahlin, Acibadem University Dspace, Efe, C, Tascilar, K, Gerussi, A, Bolis, F, Lammert, C, Ebik, B, Stattermayer, A, Cengiz, M, Gokce, D, Cristoferi, L, Peralta, M, Massoumi, H, Montes, P, Cerda, E, Rigamonti, C, Yapali, S, Adali, G, Caliskan, A, Balaban, Y, Eren, F, Eskazan, T, Barutcu, S, Lytvyak, E, Zazueta, G, Kayhan, M, Heurgue-Berlot, A, De Martin, E, Yavuz, A, Biyik, M, Narro, G, Duman, S, Hernandez, N, Gatselis, N, Aguirre, J, Idilman, R, Silva, M, Mendizabal, M, Atay, K, Guzelbulut, F, Dhanasekaran, R, Montano-Loza, A, Dalekos, G, Ridruejo, E, Invernizzi, P, and Wahlin, S
Subjects: Adult, Aged, 80 and over, Male, COVID-19 Vaccines, Adolescent, SARS-CoV-2, Vaccination, Immunology, Liver failure, COVID-19, Autoimmunity, Middle Aged, Breakthrough infection, Young Adult, Hepatitis, Autoimmune, COVID-19 Testing, Humans, Immunology and Allergy, Female, Vaccine, BNT162 Vaccine, Immunosuppression, Aged, Retrospective Studies
Abstract: Background: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. Patients and methods: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression. Results: We included 413 (258 unvaccinated and 155 vaccinated) patients (81\%, female) with a median age of 52 (range: 17-85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4\% vs. 14.2\%), need for any supplemental oxygen (29.5\% vs. 9\%) and mortality (7\% vs. 0.6\%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio {[}aOR] 0.18, 95\% confidence interval {[}CI], 0.10-0.31). Overall, vaccination against SARSCoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95\% CI 0.11-0.35). Conclusions: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH.
Published: 2022

31. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis

Author: Efe, C., Lammert, C., Taşçılar, K., Dhanasekaran, R., Ebik, B., Higuera-de la Tijera, F., Calışkan, A.R., Peralta, M., Gerussi, A., Massoumi, H., Catana, A.M., Purnak, T., Rigamonti, C., Aldana, A.J. Gomez, Khakoo, N., Nazal, L., Frager, S., Demir, N., Irak, K., Melekoğlu-Ellik, Z., Kacmaz, H., Balaban, Y., Atay, K., Eren, F., Alvares-da-Silva, M.R., Cristoferi, L., Urzua, Á., Eşkazan, T., Magro, B., Snijders, R.J.A.L.M., Barutçu, S., Lytvyak, E., Zazueta, G.M., Demirezer-Bolat, A., Aydın, M., Heurgue-Berlot, A., Martin, E., Ekin, N., Yıldırım, S., Yavuz, A., Bıyık, M., Narro, G.C., Kıyıcı, M., Akyıldız, M., Kahramanoğlu-Aksoy, E., Vincent, M., Carr, R.M., Günşar, F., Reyes, E.C., Harputluoğlu, M., Aloman, C., Gatselis, N.K., Üstündağ, Y., Brahm, J., Vargas, N.C.E., Güzelbulut, F., Garcia, S.R., Aguirre, J., Anders, M., Ratusnu, N., Hatemi, I., Mendizabal, M., Floreani, A., Fagiuoli, S., Silva, M., Idilman, R., Satapathy, S.K., Silveira, M., Drenth, J.P.H., Dalekos, G.N., Assis, D.N., Björnsson, E., Boyer, J.L., Yoshida, E.M., Invernizzi, P., Levy, C., Montano-Loza, A.J., Schiano, T.D., Ridruejo, E., Wahlin, S., Efe, C., Lammert, C., Taşçılar, K., Dhanasekaran, R., Ebik, B., Higuera-de la Tijera, F., Calışkan, A.R., Peralta, M., Gerussi, A., Massoumi, H., Catana, A.M., Purnak, T., Rigamonti, C., Aldana, A.J. Gomez, Khakoo, N., Nazal, L., Frager, S., Demir, N., Irak, K., Melekoğlu-Ellik, Z., Kacmaz, H., Balaban, Y., Atay, K., Eren, F., Alvares-da-Silva, M.R., Cristoferi, L., Urzua, Á., Eşkazan, T., Magro, B., Snijders, R.J.A.L.M., Barutçu, S., Lytvyak, E., Zazueta, G.M., Demirezer-Bolat, A., Aydın, M., Heurgue-Berlot, A., Martin, E., Ekin, N., Yıldırım, S., Yavuz, A., Bıyık, M., Narro, G.C., Kıyıcı, M., Akyıldız, M., Kahramanoğlu-Aksoy, E., Vincent, M., Carr, R.M., Günşar, F., Reyes, E.C., Harputluoğlu, M., Aloman, C., Gatselis, N.K., Üstündağ, Y., Brahm, J., Vargas, N.C.E., Güzelbulut, F., Garcia, S.R., Aguirre, J., Anders, M., Ratusnu, N., Hatemi, I., Mendizabal, M., Floreani, A., Fagiuoli, S., Silva, M., Idilman, R., Satapathy, S.K., Silveira, M., Drenth, J.P.H., Dalekos, G.N., Assis, D.N., Björnsson, E., Boyer, J.L., Yoshida, E.M., Invernizzi, P., Levy, C., Montano-Loza, A.J., Schiano, T.D., Ridruejo, E., and Wahlin, S.
Abstract: Item does not contain fulltext, BACKGROUND: We investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH). PATIENTS AND METHODS: Data of AIH patients with laboratory confirmed COVID-19 were retrospectively collected from 15 countries. The outcomes of AIH patients who were on immunosuppression at the time of COVID-19 were compared to patients who were not on AIH medication. The clinical courses of COVID-19 were classified as (i)-no hospitalization, (ii)-hospitalization without oxygen supplementation, (iii)-hospitalization with oxygen supplementation by nasal cannula or mask, (iv)-intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v)-ICU admission with invasive mechanical ventilation or (vi)-death and analysed using ordinal logistic regression. RESULTS: We included 254 AIH patients (79.5%, female) with a median age of 50 (range, 17-85) years. At the onset of COVID-19, 234 patients (92.1%) were on treatment with glucocorticoids (n = 156), thiopurines (n = 151), mycophenolate mofetil (n = 22) or tacrolimus (n = 16), alone or in combinations. Overall, 94 (37%) patients were hospitalized and 18 (7.1%) patients died. Use of systemic glucocorticoids (adjusted odds ratio [aOR] 4.73, 95% CI 1.12-25.89) and thiopurines (aOR 4.78, 95% CI 1.33-23.50) for AIH was associated with worse COVID-19 severity, after adjusting for age-sex, comorbidities and presence of cirrhosis. Baseline treatment with mycophenolate mofetil (aOR 3.56, 95% CI 0.76-20.56) and tacrolimus (aOR 4.09, 95% CI 0.69-27.00) were also associated with more severe COVID-19 courses in a smaller subset of treated patients. CONCLUSION: Baseline treatment with systemic glucocorticoids or thiopurines prior to the onset of COVID-19 was significantly associated with COVID-19 severity in patients with AIH.
Published: 2022

32. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis

Author: Efe, C, Lammert, C, Tascilar, K, Dhanasekaran, R, Ebik, B, Higuera-de la Tijera, F, Caliskan, A, Peralta, M, Gerussi, A, Massoumi, H, Catana, A, Purnak, T, Rigamonti, C, Aldana, A, Khakoo, N, Nazal, L, Frager, S, Demir, N, Irak, K, Melekoglu-Ellik, Z, Kacmaz, H, Balaban, Y, Atay, K, Eren, F, Alvares-da-Silva, M, Cristoferi, L, Urzua, A, Eskazan, T, Magro, B, Snijders, R, Barutcu, S, Lytvyak, E, Zazueta, G, Demirezer-Bolat, A, Aydin, M, Heurgue-Berlot, A, De Martin, E, Ekin, N, Yildirim, S, Yavuz, A, Biyik, M, Narro, G, Kiyici, M, Akyildiz, M, Kahramanoglu-Aksoy, E, Vincent, M, Carr, R, Gunsar, F, Reyes, E, Harputluoglu, M, Aloman, C, Gatselis, N, Ustundag, Y, Brahm, J, Vargas, N, Guzelbulut, F, Garcia, S, Aguirre, J, Anders, M, Ratusnu, N, Hatemi, I, Mendizabal, M, Floreani, A, Fagiuoli, S, Silva, M, Idilman, R, Satapathy, S, Silveira, M, Drenth, J, Dalekos, G, Assis, D, Bjornsson, E, Boyer, J, Yoshida, E, Invernizzi, P, Levy, C, Montano-Loza, A, Schiano, T, Ridruejo, E, Wahlin, S, Caliskan, AR, Catana, AM, Aldana, AJG, Alvares-da-Silva, MR, Zazueta, GM, Narro, GC, Carr, RM, Reyes, EC, Gatselis, NK, Vargas, NCE, Garcia, SR, Satapathy, SK, Drenth, JPH, Dalekos, GN, Assis, DN, Boyer, JL, Yoshida, EM, Montano-Loza, AJ, Schiano, TD, Efe, C, Lammert, C, Tascilar, K, Dhanasekaran, R, Ebik, B, Higuera-de la Tijera, F, Caliskan, A, Peralta, M, Gerussi, A, Massoumi, H, Catana, A, Purnak, T, Rigamonti, C, Aldana, A, Khakoo, N, Nazal, L, Frager, S, Demir, N, Irak, K, Melekoglu-Ellik, Z, Kacmaz, H, Balaban, Y, Atay, K, Eren, F, Alvares-da-Silva, M, Cristoferi, L, Urzua, A, Eskazan, T, Magro, B, Snijders, R, Barutcu, S, Lytvyak, E, Zazueta, G, Demirezer-Bolat, A, Aydin, M, Heurgue-Berlot, A, De Martin, E, Ekin, N, Yildirim, S, Yavuz, A, Biyik, M, Narro, G, Kiyici, M, Akyildiz, M, Kahramanoglu-Aksoy, E, Vincent, M, Carr, R, Gunsar, F, Reyes, E, Harputluoglu, M, Aloman, C, Gatselis, N, Ustundag, Y, Brahm, J, Vargas, N, Guzelbulut, F, Garcia, S, Aguirre, J, Anders, M, Ratusnu, N, Hatemi, I, Mendizabal, M, Floreani, A, Fagiuoli, S, Silva, M, Idilman, R, Satapathy, S, Silveira, M, Drenth, J, Dalekos, G, Assis, D, Bjornsson, E, Boyer, J, Yoshida, E, Invernizzi, P, Levy, C, Montano-Loza, A, Schiano, T, Ridruejo, E, Wahlin, S, Caliskan, AR, Catana, AM, Aldana, AJG, Alvares-da-Silva, MR, Zazueta, GM, Narro, GC, Carr, RM, Reyes, EC, Gatselis, NK, Vargas, NCE, Garcia, SR, Satapathy, SK, Drenth, JPH, Dalekos, GN, Assis, DN, Boyer, JL, Yoshida, EM, Montano-Loza, AJ, and Schiano, TD
Abstract: Background: We investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH). Patients and methods: Data of AIH patients with laboratory confirmed COVID-19 were retrospectively collected from 15 countries. The outcomes of AIH patients who were on immunosuppression at the time of COVID-19 were compared to patients who were not on AIH medication. The clinical courses of COVID-19 were classified as (i)-no hospitalization, (ii)-hospitalization without oxygen supplementation, (iii)-hospitalization with oxygen supplementation by nasal cannula or mask, (iv)-intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v)-ICU admission with invasive mechanical ventilation or (vi)-death and analysed using ordinal logistic regression. Results: We included 254 AIH patients (79.5%, female) with a median age of 50 (range, 17-85) years. At the onset of COVID-19, 234 patients (92.1%) were on treatment with glucocorticoids (n = 156), thiopurines (n = 151), mycophenolate mofetil (n = 22) or tacrolimus (n = 16), alone or in combinations. Overall, 94 (37%) patients were hospitalized and 18 (7.1%) patients died. Use of systemic glucocorticoids (adjusted odds ratio [aOR] 4.73, 95% CI 1.12-25.89) and thiopurines (aOR 4.78, 95% CI 1.33-23.50) for AIH was associated with worse COVID-19 severity, after adjusting for age-sex, comorbidities and presence of cirrhosis. Baseline treatment with mycophenolate mofetil (aOR 3.56, 95% CI 0.76-20.56) and tacrolimus (aOR 4.09, 95% CI 0.69-27.00) were also associated with more severe COVID-19 courses in a smaller subset of treated patients. Conclusion: Baseline treatment with systemic glucocorticoids or thiopurines prior to the onset of COVID-19 was significantly associated with COVID-19 severity in patients with AIH.
Published: 2022

33. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis

Author: Akyıldız, Murat (ORCID 0000-0002-2080-7528 & YÖK ID 123080), Efe, Cumalı; Lammert, Craig; Taşçılar, Koray; Dhanasekaran, Renumathy; Ebik, Berat; Higuera-de la Tijera, Fatima; Çalışkan, Ali R.; Peralta, Mirta; Gerussi, Alessio; Massoumi, Hatef; Catana, Andreea M.; Purnak, Tuğrul; Rigamonti, Cristina; Aldana, Andres J. G.; Khakoo, Nidah; Nazal, Leyla; Frager, Shalom; Demir, Nurhan; Irak, Kader; Melekoğlu-Ellik, Zeynep; Kaçmaz, Hüseyin; Balaban, Yasemin; Atay, Kadri; Eren, Fatih; Alvares-da-Silva, Mario R.; Cristoferi, Laura; Urzua, Alvaro; Eskazan, Tugce; Magro, Bianca; Snijders, Romee; Barutçu, Sezgin; Lytvyak, Ellina; Zazueta, Godolfino M.; Demirezer-Bolat, Aylin; Aydın, Mesut; Heurgue-Berlot, Alexandra; De Martin, Eleonora; Ekin, Nazım; Yıldırım, Sumeyra; Yavuz, Ahmet; Bıyık, Murat; Narro, Graciela C.; Kıyıcı, Murat; Kahramanoğlu-Aksoy, Evrim; Vincent, Maria; Carr, Rotonya M.; Günsar, Fulya; Reyes, Eira C.; Harputluoğlu, Murat; Aloman, Costica; Gatselis, Nikolaos K.; Üstündağ, Yücel; Brahm, Javier; Vargas, Nataly C. E.; Güzelbulut, Fatih; Garcia, Sandro R.; Aguirre, Jonathan; Anders, Margarita; Ratusnu, Natalia; Hatemi, İbrahim; Mendizabal, Manuel; Floreani, Annarosa; Fagiuoli, Stefano; Silva, Marcelo; İdilman, Ramazan; Satapathy, Sanjaya K.; Silveira, Marina; Drenth, Joost P. H.; Dalekos, George N.; Assis, David N.; Bjornsson, Einar; Boyer, James L.; Yoshida, Eric M.; Invernizzi, Pietro; Levy, Cynthia; Montano-Loza, Aldo J.; Schiano, Thomas D.; Ridruejo, Ezequiel; Wahlin, Staffan, School of Medicine, Akyıldız, Murat (ORCID 0000-0002-2080-7528 & YÖK ID 123080), Efe, Cumalı; Lammert, Craig; Taşçılar, Koray; Dhanasekaran, Renumathy; Ebik, Berat; Higuera-de la Tijera, Fatima; Çalışkan, Ali R.; Peralta, Mirta; Gerussi, Alessio; Massoumi, Hatef; Catana, Andreea M.; Purnak, Tuğrul; Rigamonti, Cristina; Aldana, Andres J. G.; Khakoo, Nidah; Nazal, Leyla; Frager, Shalom; Demir, Nurhan; Irak, Kader; Melekoğlu-Ellik, Zeynep; Kaçmaz, Hüseyin; Balaban, Yasemin; Atay, Kadri; Eren, Fatih; Alvares-da-Silva, Mario R.; Cristoferi, Laura; Urzua, Alvaro; Eskazan, Tugce; Magro, Bianca; Snijders, Romee; Barutçu, Sezgin; Lytvyak, Ellina; Zazueta, Godolfino M.; Demirezer-Bolat, Aylin; Aydın, Mesut; Heurgue-Berlot, Alexandra; De Martin, Eleonora; Ekin, Nazım; Yıldırım, Sumeyra; Yavuz, Ahmet; Bıyık, Murat; Narro, Graciela C.; Kıyıcı, Murat; Kahramanoğlu-Aksoy, Evrim; Vincent, Maria; Carr, Rotonya M.; Günsar, Fulya; Reyes, Eira C.; Harputluoğlu, Murat; Aloman, Costica; Gatselis, Nikolaos K.; Üstündağ, Yücel; Brahm, Javier; Vargas, Nataly C. E.; Güzelbulut, Fatih; Garcia, Sandro R.; Aguirre, Jonathan; Anders, Margarita; Ratusnu, Natalia; Hatemi, İbrahim; Mendizabal, Manuel; Floreani, Annarosa; Fagiuoli, Stefano; Silva, Marcelo; İdilman, Ramazan; Satapathy, Sanjaya K.; Silveira, Marina; Drenth, Joost P. H.; Dalekos, George N.; Assis, David N.; Bjornsson, Einar; Boyer, James L.; Yoshida, Eric M.; Invernizzi, Pietro; Levy, Cynthia; Montano-Loza, Aldo J.; Schiano, Thomas D.; Ridruejo, Ezequiel; Wahlin, Staffan, and School of Medicine
Abstract: Background: we investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH). Patients and methods: data of AIH patients with laboratory confirmed COVID-19 were retrospectively collected from 15 countries. The outcomes of AIH patients who were on immunosuppression at the time of COVID-19 were compared to patients who were not on AIH medication. The clinical courses of COVID-19 were classified as (i)-no hospitalization, (ii)-hospitalization without oxygen supplementation, (iii)-hospitalization with oxygen supplementation by nasal cannula or mask, (iv)-intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v)-ICU admission with invasive mechanical ventilation or (vi)-death and analysed using ordinal logistic regression. Results: we included 254 AIH patients (79.5%, female) with a median age of 50 (range, 17-85) years. At the onset of COVID-19, 234 patients (92.1%) were on treatment with glucocorticoids (n = 156), thiopurines (n = 151), mycophenolate mofetil (n = 22) or tacrolimus (n = 16), alone or in combinations. Overall, 94 (37%) patients were hospitalized and 18 (7.1%) patients died. Use of systemic glucocorticoids (adjusted odds ratio [aOR] 4.73, 95% CI 1.12-25.89) and thiopurines (aOR 4.78, 95% CI 1.33-23.50) for AIH was associated with worse COVID-19 severity, after adjusting for age-sex, comorbidities and presence of cirrhosis. Baseline treatment with mycophenolate mofetil (aOR 3.56, 95% CI 0.76-20.56) and tacrolimus (aOR 4.09, 95% CI 0.69-27.00) were also associated with more severe COVID-19 courses in a smaller subset of treated patients. Conclusion: baseline treatment with systemic glucocorticoids or thiopurines prior to the onset of COVID-19 was significantly associated with COVID-19 severity in patients with AIH., Italian Ministry of University and Research (MIUR) Department of Excellence; Project PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic)
Published: 2022

34. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

Author: Abou-Alfa, Ghassan K., primary, Chan, Stephen Lam, additional, Kudo, Masatoshi, additional, Lau, George, additional, Kelley, Robin Kate, additional, Furuse, Junji, additional, Sukeepaisarnjaroen, Wattana, additional, Kang, Yoon-Koo, additional, Dao, Tu V., additional, De Toni, Enrico N., additional, Rimassa, Lorenza, additional, Breder, Valeriy Vladimirovich, additional, Vasilyev, Alexander, additional, Heurgue, Alexandra, additional, Tam, Vincent, additional, Mody, Kabir, additional, Thungappa, Satheesh Chiradoni, additional, He, Philip, additional, Negro, Alejandra, additional, and Sangro, Bruno, additional
Published: 2022
Full Text: View/download PDF

35. Recent (non-cirrhotic) extrahepatic portal vein obstruction

Author: Alexandra Heurgue, Dominique Valla, Dominique Debray, Stéphanie Franchi-Abella, Audrey Payancé, Dalila Habes, Mathias Brugel, Virginia Hernández-Gea, Sophie Hillaire, Christophe Bureau, Aurélie Plessier, Bertrand Condat, and Danielle Dutheil
Subjects: medicine.medical_specialty, Hepatology, Portal Vein, business.industry, Gastroenterology, Portal vein obstruction, medicine.disease, Thrombosis, Practice Guidelines as Topic, Humans, Medicine, Vascular Diseases, Radiology, business
Published: 2020

36. Practice guidelines Non-invasive diagnosis and follow-up of primary sclerosing cholangitis

Author: Chazouilleres, Olivier, Potier, Pascal, Bouzbib, Charlotte, Hanslik, Bertrand, Heurgue, Alexandra, Nguyen-Khac, Eric, Gournay, Jerome, Tanne, Florence, Bureau, Christophe, Bourliere, Marc, Ganne-Carrie, Nathalie, Ledinghen, Victor, Service d'Hépato-gastro-entérologie [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional d'Orléans (CHRO), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Groupe de Recherche sur l'alcool et les pharmacodépendances - UMR INSERM_S 1247 (GRAP), Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Maladies de l'Appareil Digestif, Université de Nantes (UN), Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital Saint-Joseph [Marseille], Génomique fonctionnelle des tumeurs solides = Functional Genomics of Solid Tumors [CRC] (FunGeST), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), CHU Bordeaux [Bordeaux], and DESSAIVRE, Louise
Subjects: [SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], digestive system, digestive system diseases
Abstract: International audience; Primary sclerosing cholangitis (PSC) is a rare and chronic cholestatic liver disease of unknown cause commonly associated with inflammatory bowel disease (IBD) and characterized by progressive obliterative fibro-inflammation of the biliary tree. Although the natural course is highly variable, PSC is often progressive, leading to biliary cirrhosis and its complications. In addition, PSC is a condition harbouring broad neoplastic potential with increased susceptibility for the development of both biliary and colon cancer. As in other chronic liver diseases, non-invasive methods play a major role in the diagnosis and monitoring of PSC. MR cholangiography is the key exam for the diagnosis and has replaced diagnostic endoscopic retrograde cholangiopancreatography (ERCP). A strict and standardised protocol for carrying out MR cholangiography is recommended. Liver stiffness measured by FibroScan (R) correlates with the degree of liver fibrosis, has a prognostic value and should be repeated during follow-up. Invasive methods still play an important role, especially ERCP which is indicated for therapeutic purposes or for endo-biliary sample collection in suspected cholangiocarcinoma (following discussion in a multidisciplinary team meeting) and total colonoscopy which is recommended at the initial diagnosis of any PSC and annually in patients with IBD. (c) 2021 Elsevier Masson SAS. All rights reserved. .101775 SAS. All rights reserved.
Published: 2022

37. Non-invasive diagnosis and follow-up of primary biliary cholangitis

Author: Pascal Potier, Marie Decraecker, Florence Tanné, Christophe Bureau, Victor de Lédinghen, Nathalie Ganne-Carrié, Bertrand Hanslik, M. Bourlière, Alexandra Heurgue, Christophe Corpechot, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de référence des Maladies Vasculaires du Foie [Paris] (FILFOIE), Centre de référence pour les maladies biliaires inflammatoires et les hépatites auto-immunes [Paris] (CRMBIHAI), Health Care Provider of the European Reference Network onRare Liver Disorders (ERN-Liver), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Centre Hospitalier Régional d'Orléans (CHRO), Centre Montpellierain des maladies du foie et de l’appareil digestif [Montpellier] (C2MFAD), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Bordeaux Research In Translational Oncology [Bordeaux] (BaRITOn), Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital Saint-Joseph [Marseille], Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Dupuis, Christine, and École pratique des hautes études (EPHE)
Subjects: medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Cholangitis, Liver Cirrhosis, Biliary, [SDV]Life Sciences [q-bio], Non invasive, Gastroenterology, Autoantibody, medicine.disease, Chronic inflammatory disease, PBC, [SDV] Life Sciences [q-bio], Bile Ducts, Intrahepatic, Liver stiffness, Internal medicine, Chronic cholestasis, medicine, Portal hypertension, Humans, business, Histological examination, Follow-Up Studies
Abstract: International audience; Non-invasive diagnosis and follow-up of primary biliary cholangitis Summary Primary biliary cholangitis (PBC) is a chronic inflammatory disease of the intrahepatic bile ducts [1]. It is characterised biologically by chronic cholestasis associated with the presence of specific autoantibodies, and histologically by lesions of nonsuppurative destructive cholangitis. If left untreated it can progress to cirrhosis, portal hypertension and liver failure. Diagnosis, staging and follow-up are largely based on non-or minimally-invasive assessment (blood tests, ultrasound, liver stiffness measurement). Histological examination of the liver and upper gastrointestinal endoscopy are sometimes necessary, but their indications remain limited. The purpose of this chapter is to provide the clinicians with what should be known about the non-invasive assessment of PBC and to provide specific recommendations for clinical practice.
Published: 2022

38. New cases of Budd-Chiari syndrome and splanchnic vein thrombosis after COVID-19 vaccination-a vascular liver disease group (VALDIG) initiative

Author: Raoel Maan, Aurélie Plessier, Louise China, David Patch, Anna Baiges, Juan Carlos Garcia Pagan, Virginia Hernandez-Gea, Marie-Noëlle Hilleret, E.T.T.L. Tjwa, Ilias Kounis, Christophe Bureau, Baptiste Giguet, Alexandra Heurgue-Berlot, Isabelle Ollivier-Hourmand, Xavier Causse, Filipe Gaio Castro Nery, Mandy Lauw, and Sarwa Darwish Murad
Subjects: Hepatology
Published: 2022

39. Non-invasive diagnosis and follow-up of primary sclerosing cholangitis

Author: Chazouillères, Olivier, primary, Potier, Pascal, additional, Bouzbib, Charlotte, additional, Hanslik, Bertrand, additional, Heurgue, Alexandra, additional, NGuyen-Khac, Eric, additional, Gournay, Jérôme, additional, Tanne, Florence, additional, Bureau, Christophe, additional, Bourlière, Marc, additional, Ganne-Carrié, Nathalie, additional, and de Lédinghen, Victor, additional
Published: 2022
Full Text: View/download PDF

40. Non-invasive diagnosis and follow-up of primary biliary cholangitis

Author: Corpechot, Christophe, primary, Heurgue, Alexandra, additional, Tanne, Florence, additional, Potier, Pascal, additional, Hanslik, Bertrand, additional, Decraecker, Marie, additional, de Lédinghen, Victor, additional, Ganne-Carrié, Nathalie, additional, Bureau, Christophe, additional, and Bourlière, Marc, additional
Published: 2022
Full Text: View/download PDF

41. Non-invasive diagnosis and follow-up of autoimmune hepatitis

Author: Lemoinne, Sara, primary, Heurgue, Alexandra, additional, Bouzbib, Charlotte, additional, Hanslik, Bertrand, additional, Gournay, Jérôme, additional, Nguyen-Khac, Eric, additional, Bureau, Christophe, additional, de Lédinghen, Victor, additional, Ganne-Carrié, Nathalie, additional, and Bourlière, Marc, additional
Published: 2022
Full Text: View/download PDF

42. Effects of immunosuppressive drugs on COVID‐19 severity in patients with autoimmune hepatitis

Author: Efe, Cumali, primary, Lammert, Craig, additional, Taşçılar, Koray, additional, Dhanasekaran, Renumathy, additional, Ebik, Berat, additional, Higuera‐de la Tijera, Fatima, additional, Calışkan, Ali R., additional, Peralta, Mirta, additional, Gerussi, Alessio, additional, Massoumi, Hatef, additional, Catana, Andreea M., additional, Purnak, Tugrul, additional, Rigamonti, Cristina, additional, Aldana, Andres J. G., additional, Khakoo, Nidah, additional, Nazal, Leyla, additional, Frager, Shalom, additional, Demir, Nurhan, additional, Irak, Kader, additional, Melekoğlu‐Ellik, Zeynep, additional, Kacmaz, Hüseyin, additional, Balaban, Yasemin, additional, Atay, Kadri, additional, Eren, Fatih, additional, Alvares‐da‐Silva, Mario R., additional, Cristoferi, Laura, additional, Urzua, Álvaro, additional, Eşkazan, Tuğçe, additional, Magro, Bianca, additional, Snijders, Romee, additional, Barutçu, Sezgin, additional, Lytvyak, Ellina, additional, Zazueta, Godolfino M., additional, Demirezer‐Bolat, Aylin, additional, Aydın, Mesut, additional, Heurgue‐Berlot, Alexandra, additional, De Martin, Eleonora, additional, Ekin, Nazım, additional, Yıldırım, Sümeyra, additional, Yavuz, Ahmet, additional, Bıyık, Murat, additional, Narro, Graciela C., additional, Kıyıcı, Murat, additional, Akyıldız, Murat, additional, Kahramanoğlu‐Aksoy, Evrim, additional, Vincent, Maria, additional, Carr, Rotonya M, additional, Günşar, Fulya, additional, Reyes, Eira C., additional, Harputluoğlu, Murat, additional, Aloman, Costica, additional, Gatselis, Nikolaos K., additional, Üstündağ, Yücel, additional, Brahm, Javier, additional, Vargas, Nataly C. E., additional, Güzelbulut, Fatih, additional, Garcia, Sandro R., additional, Aguirre, Jonathan, additional, Anders, Margarita, additional, Ratusnu, Natalia, additional, Hatemi, Ibrahim, additional, Mendizabal, Manuel, additional, Floreani, Annarosa, additional, Fagiuoli, Stefano, additional, Silva, Marcelo, additional, Idilman, Ramazan, additional, Satapathy, Sanjaya K., additional, Silveira, Marina, additional, Drenth, Joost P. H., additional, Dalekos, George N, additional, N.Assis, David, additional, Björnsson, Einar, additional, Boyer, James L., additional, Yoshida, Eric M., additional, Invernizzi, Pietro, additional, Levy, Cynthia, additional, Montano‐Loza, Aldo J., additional, Schiano, Thomas D., additional, Ridruejo, Ezequiel, additional, and Wahlin, Staffan, additional
Published: 2021
Full Text: View/download PDF

43. Non-invasive diagnosis and follow-up of autoimmune hepatitis

Author: Charlotte Bouzbib, M. Bourlière, Alexandra Heurgue, Jérôme Gournay, Christophe Bureau, Sara Lemoinne, Bertrand Hanslik, Victor de Lédinghen, Nathalie Ganne-Carrié, Eric Nguyen-Khac, CHU Amiens-Picardie, Groupe de Recherche sur l'alcool et les pharmacodépendances - UMR INSERM_S 1247 (GRAP), Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), DESSAIVRE, Louise, Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Montpellierain des maladies du foie et de l’appareil digestif [Montpellier] (C2MFAD), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Bordeaux Research In Translational Oncology [Bordeaux] (BaRITOn), Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Saint-Joseph [Marseille], Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Lemoinne, Sara, and École Pratique des Hautes Études (EPHE)
Subjects: medicine.medical_specialty, [SDV]Life Sciences [q-bio], Cholangitis, Sclerosing, Disease, Autoimmune hepatitis, Chronic liver disease, overlap syndrome, Gastroenterology, Primary sclerosing cholangitis, Biliary disease, Liver disease, immune system diseases, Internal medicine, medicine, Humans, Hepatology, autoimmune hepatitis, business.industry, Liver Cirrhosis, Biliary, Autoantibody, Overlap syndrome, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, medicine.disease, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, digestive system diseases, [SDV] Life Sciences [q-bio], Hepatitis, Autoimmune, business, Follow-Up Studies
Abstract: International audience; Autoimmune hepatitis (AIH) is a liver disease characterised by necrotico-inflammatory lesions of hepatocytes, the presence of specific autoantibodies and response to corticosteroid treatment. AIH must be considered in any patient with acute or chronic liver disease. As there is no pathognomonic sign of AIH, the diagnosis is based on a combination of clinical, biological, immunological and histological findings, after excluding other causes of liver disease. The clinical and biological presentation of AIH is variable and AIH can be associated with an autoimmune biliary disease, primary biliary cholangitis or primary sclerosing cholangitis in an overlap syndrome. For these reasons, diagnosis of AIH can be challenging. Even if liver histology remains essential in the diagnosis of AIH, non-invasive tests can be used at different steps of the management of AIH: diagnosis of AIH, notably diagnosis of an overlap syndrome, assessment of severity of AIH, searching for extra-hepatic disease frequently associated to AIH, evaluation of response to therapy, decision of treatment withdrawal. This review aims to provide practical guidelines for the use of non-invasive tests for the diagnosis and the follow-up of AIH. (C) 2021 Published by Elsevier Masson SAS.
Published: 2021

44. Non-invasive diagnosis and follow-up of primary sclerosing cholangitis

Author: Pascal Potier, Victor de Lédinghen, Christophe Bureau, Jérôme Gournay, Nathalie Ganne-Carrié, Florence Tanne, Charlotte Bouzbib, M. Bourlière, Alexandra Heurgue, Eric Nguyen-Khac, Olivier Chazouillères, and Bertrand Hanslik
Subjects: medicine.medical_specialty, Colorectal cancer, Biliary cirrhosis, Cholangitis, Sclerosing, digestive system, Gastroenterology, Inflammatory bowel disease, Primary sclerosing cholangitis, Cholangiography, Cholestasis, Internal medicine, medicine, Humans, Cholangiopancreatography, Endoscopic Retrograde, Endoscopic retrograde cholangiopancreatography, Hepatology, medicine.diagnostic_test, business.industry, medicine.disease, Inflammatory Bowel Diseases, digestive system diseases, Bile Ducts, Intrahepatic, Bile Duct Neoplasms, Sample collection, business, Follow-Up Studies
Abstract: Primary sclerosing cholangitis (PSC) is a rare and chronic cholestatic liver disease of unknown cause commonly associated with inflammatory bowel disease (IBD) and characterized by progressive obliterative fibro-inflammation of the biliary tree. Although the natural course is highly variable, PSC is often progressive, leading to biliary cirrhosis and its complications. In addition, PSC is a condition harbouring broad neoplastic potential with increased susceptibility for the development of both biliary and colon cancer. As in other chronic liver diseases, non-invasive methods play a major role in the diagnosis and monitoring of PSC. MR cholangiography is the key exam for the diagnosis and has replaced diagnostic endoscopic retrograde cholangiopancreatography (ERCP). A strict and standardised protocol for carrying out MR cholangiography is recommended. Liver stiffness measured by FibroScan® correlates with the degree of liver fibrosis, has a prognostic value and should be repeated during follow-up. Invasive methods still play an important role, especially ERCP which is indicated for therapeutic purposes or for endo-biliary sample collection in suspected cholangiocarcinoma (following discussion in a multidisciplinary team meeting) and total colonoscopy which is recommended at the initial diagnosis of any PSC and annually in patients with IBD.
Published: 2021

45. Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma

Author: Kevin Zarca, Maroua Mimouni, Helena Pereira, Gilles Chatellier, Valérie Vilgrain, Isabelle Durand-Zaleski, Eric Assenat, Elisabeth Delhom-Christol, Boris Guiu, Alina D. Ilonca, Julie Lonjon, Georges-Philippe Pageaux, Mohamed Abdel-Rehim, Wassim Al-laham, Mohamed Bouattour, Laurent Castera, Arnaud Dieudonné, Rachida Lebtahi, Maxime Ronot, Annie Sibert, Hélène Barraud, Christophe Bazin, Jean-Pierre Bronowicki, Valérie Laurent, Elodie Mathias, Carine Chagneau-Derrode, Rémy Perdrisot, Christine Silvain, Jean-Pierre Tasu, Patrick Borentain RenéGerolami, Olivier Mundler, Jean-Francois Seitz, Vincent Vidal, Christophe Aubé, Antoine Bouvier, Olivier Couturier, Frédéric Oberti, Laurent Vervueren, Isabelle Brenot-Rossi, Jean-Luc Raoul, Anthony Sar-ran, Julia Chalaye, Charlotte Costentin, Emmanuel Itti, Hicham Kobeiter, Alain Luciani, René Adam, Maïté Lewin, Didier Samuel, Julien Edeline, Etienne Garin, Yan Rolland, Isabelle Archambeaud, Thomas Eugene, Eric Frampas, Christophe Cassinotto, Martine Guyot, Jean-Baptiste Hiriart, Bruno Lapuyade, Julien Vergniol, Philippe Bachellier, Julien Detour, Bernard Duclos, Michel Greget, Francois Habersetzer, Alessio Imperiale, Philippe Merle, Agnès Rode, Julie Morvan, Eric Nguyen-Khac, Thierry Yzet, Guillaume Baudin, Patrick Chevallier, Abakar Mahamat, Thierry Piche, Micheline Razzouk, Patrick Hillon, Romaric Loffroy, Michel Toubeau, Julie Vincent, Gabriele Barabino, Nadia Bouarioua, Muriel Cuilleron, Marie Ecochard, Nathalie Prevot-Bitot, Vincent Leroy, Julie Roux, Christian Sengel, Valérie Bourcier, Nathalie Ganne- Carrie, Olivier Seror, Sylvie Costo, Thông Dao, Jean-Pierre Pelage, Jérôme Dumortier, Francesco Giammarile, Pierre-Jean Valette, Nadia Ghazzar, Olivier Pellerin, Julien Taieb, Pierre Weinmann, Alexandra Heurgue- Berlot, Claude Marcus, Daniele Sommacale, Maria-Angéla Castilla-Lièvre, Sophie Maitre, Lysiane Marthey, Direction de la Recherche Clinique et de l'Innovation [AP-HP] (DRCI), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre d'Investigation Clinique Henri Mondor (CIC Henri Mondor), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CIC - HEGP (CIC 1418), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Equipe 2 : ECSTRA - Epidémiologie Clinique, STatistique, pour la Recherche en Santé (CRESS - U1153), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi], Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), Département radiologie diagnostique et interventionnelle Saint Eloi [CHRU Montpellier], Pôle Digestif [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Equipe IFTIM [ImViA - EA7535], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER-Imagerie et Vision Artificielle [Dijon] (ImViA), Université de Bourgogne (UB)-Université de Bourgogne (UB), HESAM Université (HESAM)-HESAM Université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPC), HESAM Université (HESAM)-HESAM Université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), and CHU Saint-Eloi-Université de Montpellier (UM)
Subjects: Sorafenib, Oncology, medicine.medical_specialty, Randomization, Carcinoma, Hepatocellular, Tare weight, Hepatocellular carcinoma, Cost-Benefit Analysis, [SDV.CAN]Life Sciences [q-bio]/Cancer, 02 engineering and technology, 030204 cardiovascular system & hematology, Transarterial Radioembolization, 03 medical and health sciences, 020210 optoelectronics & photonics, 0302 clinical medicine, Quality of life, Internal medicine, 0202 electrical engineering, electronic engineering, information engineering, medicine, Humans, Pharmacology (medical), Yttrium radioisotopes, Survival analysis, Pharmacology, Cost–utility analysis, business.industry, Liver Neoplasms, Cost-utility analysis, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, medicine.disease, Microspheres, Quality of Life, business, medicine.drug
Abstract: International audience; Purpose: The SARAH (Sorafenib Versus Radioembolization in Advanced Hepatocellular Carcinoma) trial (ClinicalTrials.gov Identifier NCT01482442) did not show a significant survival benefit for patients treated with transarterial radioembolization (TARE) compared with continuous oral sorafenib. The improved toxicity profile of patients treated with TARE in the trial, however, could result in a quality of life benefit in economic evaluations. Our objective was to perform a cost-utility analysis of TARE versus sorafenib for locally advanced and inoperable hepatocellular carcinoma.Methods: This study used patient-level data of the SARAH trial regarding resource use, progression-free and overall survival, and quality of life for the within-trial period for the patients who received at least 1 dose of sorafenib or 1 treatment with TARE according to their randomization arm. Data were extrapolated by using a partitioned survival model that incorporated costs and health outcomes, measured in life-years and quality-adjusted life-years (QALYs).Findings: The use of TARE resulted in an average loss of 0.036 life-year and a gain of 0.006 QALY compared with sorafenib. The aerage cost for the TARE arm was €17,179 (95% CI, 9,926-24,280) higher than the sorafenib arm, for an incremental cost-effectiveness ratio of €3,153,086/QALY. The probabilistic sensitivity analysis revealed a 50% risk that the TARE strategy was dominated. TARE was consistently dominated by sorafenib or had an incremental cost-effectiveness ratio more than €450,000/QALY in all sensitivity analyses.Implications: This economic evaluation of SARAH found that using radioembolization with yttrium-90 microspheres for the treatment of hepatocellular carcinoma was not a cost-effective option at the usually accepted willingness-to-pay thresholds.
Published: 2021

46. Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial)

Author: Pereira, Helena, primary, Bouattour, Mohamed, additional, Burgio, Marco D., additional, Assenat, Eric, additional, Grégory, Jules, additional, Bronowicki, Jean-Pierre, additional, Chatellier, Gilles, additional, Vilgrain, Valérie, additional, Delhom-Christol, Elisabeth, additional, Fourcade, Marjolène, additional, Guiu, Boris, additional, Ilonca, Alina Diana, additional, Lonjon, Julie, additional, Pageaux, Georges-Philippe, additional, Abdel-Rehim, Mohamed, additional, Allaham, Wassim, additional, Castera, Laurent, additional, Dieudonné, Arnaud, additional, Lebtahi, Rachida, additional, Ronot, Maxime, additional, Sibert, Annie, additional, Chor, Hélène, additional, Devictor, Julie, additional, Barraud, Hélène, additional, Bazin, Christophe, additional, Imbert, Laetitia, additional, Laurent, Valérie, additional, Mathias, Elodie, additional, Chagneau-Derrode, Carine, additional, Gallais, Christelle, additional, Perdrisot, Rémy, additional, Silvain, Christine, additional, Tasu, Jean Pierre, additional, Borentain, Patrick, additional, Farman, Bardia, additional, Gerolami, René, additional, Mundler, Olivier, additional, Seitz, Jean-Francois, additional, Vidal, Vincent, additional, Aubé, Christophe, additional, Bouchet, Francis, additional, Bouvier, Antoine, additional, Couturier, Olivier, additional, Oberti, Frédéric, additional, Vervueren, Laurent, additional, Brenot-Rossi, Isabelle, additional, Darreon, Julien, additional, Raoul, Jean Luc, additional, Sarran, Anthony, additional, Chalaye, Julia, additional, Costentin, Charlotte, additional, Itti, Emmanuel, additional, Kobeiter, Hicham, additional, Luciani, Alain, additional, Masset, Hélène, additional, Adam, René, additional, Lewin, Maïté, additional, Samuel, Didier, additional, Edeline, Julien, additional, Garin, Etienne, additional, Laffont, Sophie, additional, Rolland, Yan, additional, Archambeaud, Isabelle, additional, Carlier, Thomas, additional, Eugene, Thomas, additional, Frampas, Eric, additional, Cassinotto, Christophe, additional, Guyot, Martine, additional, Hiriart, Jean-Baptiste, additional, Lapuyade, Bruno, additional, Tendero, Karine, additional, Vergniol, Julien, additional, Bachellier, Philippe, additional, Détour, Julien, additional, Duclos, Bernard, additional, Greget, Michel, additional, Habersetzer, Francois, additional, Imperiale, Alessio, additional, Enderlin, Elise, additional, Merle, Philippe, additional, Rode, Agnès, additional, Morvan, Julie, additional, Nguyen-Khac, Eric, additional, Talbot, Antoine, additional, Yzet, Thierry, additional, Baudin, Guillaume, additional, Chevallier, Patrick, additional, Mahamat, Abakar, additional, Maurel, Fabien, additional, Piche, Thierry, additional, Razzouk, Micheline, additional, Hillon, Patrick, additional, Loffroy, Romaric, additional, Toubeau, Michel, additional, Vincent, Julie, additional, Vrigneaud, Jean-Marc, additional, Barabino, Gabriele, additional, Bouarioua, Nadia, additional, Cuilleron, Muriel, additional, Ecochard, Marie, additional, Prevot-Bitot, Nathalie, additional, Rousset, Evelyne, additional, Leroy, Vincent, additional, Reboulet, Ghislaine, additional, Roux, Julie, additional, Sengel, Christian, additional, Bourcier, Valérie, additional, Ganne-Carrie, Nathalie, additional, Seror, Olivier, additional, Costo, Sylvie, additional, Dao, Thông, additional, Desmonts, Cédric, additional, Pelage, Jean-Pierre, additional, Defez, Didier, additional, Dumortier, Jérôme, additional, Giammarile, Francesco, additional, Valette, Pierre-Jean, additional, Bernardini, Michela, additional, Ghazar, Nadia, additional, Pellerin, Olivier, additional, Taieb, Julien, additional, Weinmann, Pierre, additional, Heurgue-Berlot, Alexandra, additional, Marcus, Claude, additional, Sommacale, Daniele, additional, Castilla-Lièvre, Maria-Angéla, additional, Forbes, Aurélie, additional, Maitre, Sophie, additional, and Marthey, Lysiane, additional
Published: 2021
Full Text: View/download PDF

47. Localization and Characterization of the Gene Encoding Release Factor RF3 in Escherichia coli

Author: Grentzmann, Guido, Brechemier-Baey, Dominique, Heurgue, Valerie, Mora, Liliana, and Buckingham, Richard H.
Published: 1994

48. Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma

Author: Zarca, Kevin, primary, Mimouni, Maroua, additional, Pereira, Helena, additional, Chatellier, Gilles, additional, Vilgrain, Valérie, additional, Durand-Zaleski, Isabelle, additional, Assenat, Eric, additional, Delhom-Christol, Elisabeth, additional, Guiu, Boris, additional, Ilonca, Alina D., additional, Lonjon, Julie, additional, Pageaux, Georges-Philippe, additional, Abdel-Rehim, Mohamed, additional, Al-laham, Wassim, additional, Bouattour, Mohamed, additional, Castera, Laurent, additional, Dieudonné, Arnaud, additional, Lebtahi, Rachida, additional, Ronot, Maxime, additional, Sibert, Annie, additional, Barraud, Hélène, additional, Bazin, Christophe, additional, Bronowicki, Jean-Pierre, additional, Laurent, Valérie, additional, Mathias, Elodie, additional, Chagneau-Derrode, Carine, additional, Perdrisot, Rémy, additional, Silvain, Christine, additional, Tasu, Jean-Pierre, additional, RenéGerolami, Patrick Borentain, additional, Mundler, Olivier, additional, Seitz, Jean-Francois, additional, Vidal, Vincent, additional, Aubé, Christophe, additional, Bouvier, Antoine, additional, Couturier, Olivier, additional, Oberti, Frédéric, additional, Vervueren, Laurent, additional, Brenot-Rossi, Isabelle, additional, Raoul, Jean-Luc, additional, Sar-ran, Anthony, additional, Chalaye, Julia, additional, Costentin, Charlotte, additional, Itti, Emmanuel, additional, Kobeiter, Hicham, additional, Luciani, Alain, additional, Adam, René, additional, Lewin, Maïté, additional, Samuel, Didier, additional, Edeline, Julien, additional, Garin, Etienne, additional, Rolland, Yan, additional, Archambeaud, Isabelle, additional, Eugene, Thomas, additional, Frampas, Eric, additional, Cassinotto, Christophe, additional, Guyot, Martine, additional, Hiriart, Jean-Baptiste, additional, Lapuyade, Bruno, additional, Vergniol, Julien, additional, Bachellier, Philippe, additional, Detour, Julien, additional, Duclos, Bernard, additional, Greget, Michel, additional, Habersetzer, Francois, additional, Imperiale, Alessio, additional, Merle, Philippe, additional, Rode, Agnès, additional, Morvan, Julie, additional, Nguyen-Khac, Eric, additional, Yzet, Thierry, additional, Baudin, Guillaume, additional, Chevallier, Patrick, additional, Mahamat, Abakar, additional, Piche, Thierry, additional, Razzouk, Micheline, additional, Hillon, Patrick, additional, Loffroy, Romaric, additional, Toubeau, Michel, additional, Vincent, Julie, additional, Barabino, Gabriele, additional, Bouarioua, Nadia, additional, Cuilleron, Muriel, additional, Ecochard, Marie, additional, Prevot-Bitot, Nathalie, additional, Leroy, Vincent, additional, Roux, Julie, additional, Sengel, Christian, additional, Bourcier, Valérie, additional, Carrie, Nathalie Ganne-, additional, Seror, Olivier, additional, Costo, Sylvie, additional, Dao, Thông, additional, Pelage, Jean-Pierre, additional, Dumortier, Jérôme, additional, Giammarile, Francesco, additional, Valette, Pierre-Jean, additional, Ghazzar, Nadia, additional, Pellerin, Olivier, additional, Taieb, Julien, additional, Weinmann, Pierre, additional, Berlot, Alexandra Heurgue-, additional, Marcus, Claude, additional, Sommacale, Daniele, additional, Castilla-Lièvre, Maria-Angéla, additional, Maitre, Sophie, additional, and Marthey, Lysiane, additional
Published: 2021
Full Text: View/download PDF

49. Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score

Author: De Martin, Eleonora, primary, Coilly, Audrey, additional, Chazouillères, Olivier, additional, Roux, Olivier, additional, Peron, Jean-Marie, additional, Houssel-Debry, Pauline, additional, Artru, Florent, additional, Silvain, Christine, additional, Ollivier-Hourmand, Isabelle, additional, Duvoux, Christophe, additional, Heurgue, Alexandra, additional, Barge, Sandrine, additional, Ganne-Carrié, Nathalie, additional, Pageaux, Georges-Philippe, additional, Besch, Camille, additional, Bourlière, Marc, additional, Fontaine, Hélène, additional, de Ledinghen, Victor, additional, Dumortier, Jérôme, additional, Conti, Filomena, additional, Radenne, Sylvie, additional, Debette-Gratien, Marilyne, additional, Goria, Odile, additional, Durand, François, additional, Potier, Pascal, additional, Di Martino, Vincent, additional, Reboux, Noemi, additional, Ichai, Philippe, additional, Sebagh, Mylène, additional, Mathurin, Philippe, additional, Agostini, Hélène, additional, Samuel, Didier, additional, and Duclos-Vallée, Jean-Charles, additional
Published: 2021
Full Text: View/download PDF

50. Extrahepatic autoimmune diseases in primary biliary cholangitis : Prevalence and significance for clinical presentation and disease outcome

Author: Efe, Cumali, Torgutalp, Murat, Henriksson, Ida, Alalkim, Fatema, Lytvyak, Ellina, Trivedi, Hirsh, Eren, Fatih, Fischer, Janett, Chayanupatkul, Maneerat, Coppo, Claudia, Purnak, Tugrul, Muratori, Luigi, Werner, Mårten, Muratori, Paolo, Rorsman, Fredrik, Onnerhag, Kristina, Nilsson, Emma, Heurgue-Berlot, Alexandra, Demir, Nurhan, Semela, David, Kiyici, Murat, Schiano, Thomas D., Montano-Loza, Aldo J., Berg, Thomas, Ozaslan, Ersan, Yoshida, Eric M., Bonder, Alan, Marschall, Hanns-Ulrich, Beretta-Piccoli, Benedetta Terziroli, Wahlin, Staffan, Efe, Cumali, Torgutalp, Murat, Henriksson, Ida, Alalkim, Fatema, Lytvyak, Ellina, Trivedi, Hirsh, Eren, Fatih, Fischer, Janett, Chayanupatkul, Maneerat, Coppo, Claudia, Purnak, Tugrul, Muratori, Luigi, Werner, Mårten, Muratori, Paolo, Rorsman, Fredrik, Onnerhag, Kristina, Nilsson, Emma, Heurgue-Berlot, Alexandra, Demir, Nurhan, Semela, David, Kiyici, Murat, Schiano, Thomas D., Montano-Loza, Aldo J., Berg, Thomas, Ozaslan, Ersan, Yoshida, Eric M., Bonder, Alan, Marschall, Hanns-Ulrich, Beretta-Piccoli, Benedetta Terziroli, and Wahlin, Staffan
Abstract: Background and Aim: The prevalence and clinical significance of extrahepatic autoimmune diseases (EHAIDs) have not been evaluated in a large cohort of primary biliary cholangitis (PBC). Methods: The medical records of 1554 patients with PBC from 20 international centers were retrospectively reviewed. Development of decompensated cirrhosis (ascites, variceal bleeding, and/or hepatic encephalopathy) and hepatocellular carcinoma were considered clinical endpoints. Results: A total of 35 different EHAIDs were diagnosed in 440 (28.3%) patients with PBC. Patients with EHAIDs were more often female (92.5%vs86.1%,P < 0.001) and seropositive for anti-mitochondrial antibodies (88%vs84%,P = 0.05) and antinuclear antibodies and/or smooth muscle antibodies (53.8%vs43.6%,P = 0.005). At presentation, patients with EHAIDs had significantly lower levels of alkaline phosphatase (1.76vs1.98 x upper limit of normal [ULN],P = 0.006), aspartate aminotransferase (1.29vs1.50 x ULN,P < 0.001), and total bilirubin (0.53vs0.58 x ULN,P = 0.002). Patients with EHAIDs and without EHAIDs had similar rates of GLOBE high-risk status (12.3%vs16.1%,P = 0.07) and Paris II response (71.4%vs69.4%,P = 0.59). Overall, event-free survival was not different in patients with and without EHAIDs (90.8%vs90.7%,P = 0.53, log rank). Coexistence of each autoimmune thyroid diseases (10.6%), Sjogren disease (8.3%), systemic sclerosis (2.9%), rheumatoid arthritis (2.7%), systemic lupus erythematosus (1.7%), celiac disease (1.7%), psoriasis (1.5%), and inflammatory bowel diseases (1.3%) did not influence the outcome. Conclusions: Our study confirms that EHAIDs are frequently diagnosed in patients with PBC. The presence of EHAIDs may influence the clinical phenotype of PBC at presentation but has no impact on PBC outcome.
Published: 2021
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

196 results on '"Heurgue A"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources